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Debye lengthLung surfactant (LS) is a mixture of lipids and proteins that line the alveolar air–liquid interface, lowering the
interfacial tension to levels that make breathing possible. In acute respiratory distress syndrome (ARDS),
inactivation of LS is believed to play an important role in the development and severity of the disease. This review
examines the competitive adsorption of LS and surface-active contaminants, such as serum proteins, present in
the alveolarﬂuids of ARDSpatients, and how this competitive adsorption can cause normal amounts of otherwise
normal LS to be ineffective in lowering the interfacial tension. LS and serum proteins compete for the air–water
interface when both are present in solution either in the alveolar ﬂuids or in a Langmuir trough. Equilibrium
favors LS as it has the lower equilibrium surface pressure, but the smaller proteins are kinetically favored over
multi-micron LSbilayer aggregatesby faster diffusion. If albumin reaches the interface, it creates anenergybarrier
to subsequent LS adsorption that slows or prevents the adsorption of the necessary amounts of LS required to
lower surface tension. This process can be understood in terms of classic colloid stability theory in which an
energy barrier to diffusion stabilizes colloidal suspensions against aggregation. This analogy provides qualitative
and quantitative predictions regarding the origin of surfactant inactivation. An important corollary is that any
additive that promotes colloid coagulation, such as increased electrolyte concentration, multivalent ions,
hydrophilic non-adsorbing polymers such as PEG, dextran, etc. added to LS, or polyelectrolytes such as chitosan,
also promotes LS adsorption in the presence of serum proteins and helps reverse surfactant inactivation. The
theory provides quantitative tools to determine the optimal concentration of these additives and suggests that
multiple additives may have a synergistic effect. A variety of physical and chemical techniques including
isotherms, ﬂuorescence microscopy, electron microscopy and X-ray diffraction show that LS adsorption is
enhanced by this mechanism without substantially altering the structure or properties of the LS monolayer.+1 805 893 4731.
asadzinski).
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The human lung bifurcates into numerous channels (bronchi and
bronchioles) terminating in small spherical, liquid-coated chambers
[1], called alveoli, in which gas exchange occurs. The surface area in
adult lungs is ∼70 m2, about half the area of a tennis court [2–5]. This
enormous surface area maximizes the exchange of oxygen and carbon
dioxide between air and blood, but an air–water interface of this size
could contribute a signiﬁcant drain on metabolic energy as the
interface expands and contracts against surface tension. Nature has
minimized this energy drain by coating the lung air–water interface
with a thin ﬁlm of lipids and proteins, collectively called lung
surfactant (LS).
LS is composedof 90% lipids (primarilydipalmitoylphosphatidylcho-
line, DPPC) and 10% of four lung surfactant speciﬁc proteins (SP-A, B,
C, and D) [2–9]. Lung surfactant, like other surface-active substances,
adsorbs spontaneously to an air–water interface because doing so
lowers the energy of the interface [10]. Lung surfactant continues to
adsorb until the normal air–water surface tension, γ, of ∼70 mN/m
(dyne/cm) decreases to ∼30 mN/m at equilibrium [11,12]; this
equilibrium surface tension is similar for native and most clinical
replacement surfactants [13]. In normal lungs, after secretionof LS in the
form of multilamellar bodies from alveolar type II cells [14–16]
surfactant must unpack, move across the alveolar hypophase, adsorb
to the air–water interface, and then transform from bilayer to
monolayer and spread over the interface [4]. Similarly, aqueous
mixtures of surfactant, introduced into the airway of a patient with
lung disease,must travel to the periphery of the lung, adsorb and spread
to cover the air–liquid interface, despite the presence of any other
surface-active materials present in the alveoli. For both normal and
exogenous surfactant, adsorption through the liquid subphase is the
primary route of surfactant accumulation at the interface.
Why is this reduction in equilibrium surface tension so important
to breathing? Surface tension causes the pressure in an air bubble
(Pin) of radius, R, (a simple model for an alveolus with radius R)
within a conﬁning liquid (Pout) to increase according to Laplace's
equation: Pin–Pout=ΔP≈2γ/R. Breathing is initiated by motion of the
diaphragm, which induces a negative pressure (vacuum) on the
outsides of the alveoli (Pout). During breathing, since the alveolus is
connected to the outside air (at ambient pressure, Pam), the increase
in pressure in the alveolus due to surface tension, ΔP≈2γ/R, must be
such that an overall negative pressure (Pam−PinN0) remains between
the air inside and outside the body so that air ﬂows into the lungs.
Hence, surface tension requires that the diaphragm generate a lower
pressure (greater vacuum) than would be necessary in the absence of
surface tension; the lower γ, the less force (Force=Pressure
differential×surface area of lung) must be developed by the motion
of the diaphragm, and the less work (Work=Force×Distance) is
necessary for breathing. If the diaphragm cannot generate the
necessary vacuum, air no longer ﬂows into the lungs; if too much
work is required to generate this vacuum, little energy is left for
anything else. Simply put, the evolution of air-breathing required the
co-evolution of lung surfactant [17].
A second consideration necessitating lung surfactant is that at any
given time during breathing, different alveoli will be in different states
of inﬂation. This means different values of R and different Laplace
pressures, ΔP≈2γ/R, with the less inﬂated, smaller alveoli having the
larger Laplace pressures. Hence, the smaller alveoli tend to get even
smaller and eventually collapse, and their high-pressure gas contents
ﬂow to the larger alveoli with their smaller Laplace pressures [18].
The corresponding liquid layer thickens in the less inﬂated alveoli,
because the corresponding Laplace pressure inside the liquid in the
deﬂated alveoli is less than in the liquid lining more inﬂated alveoli.
The net result is that the smallest alveoli can collapse and ﬁll with
liquid and become difﬁcult to re-inﬂate. While part of the lung
collapses, other parts are over-extended.Lung surfactant solves this second problem by further reducing the
surface tension as the air–epithelial ﬂuid interface in the alveolus
shrinks during expiration. Surfactant molecules are effectively
insoluble in the alveolar liquids, which traps the surfactant at the
interface (at least over the time scales relevant to breathing). The area
available per surfactant molecule at the interface decreases alongwith
the decrease in the alveolar interfacial area. As the interfacial density
of the surfactant increases, the surfactant molecules bump into each
other more and more, which induces a force opposing the surface
tension of the liquid. This “surface pressure”,Π (Π=γw−γ; γw is the
surface tension of a clean air–water interface, 72 mN/m, and γ the
measured surface tension) exerted by the surfactant acts to expand
the interfacial area in opposition to the surface tension of the liquid–
air interface, which acts to decrease the interfacial area. These
opposing forces cause the net interfacial tension to decrease during
compression of the interface; a good lung surfactant can lower this
dynamic interfacial tension to near zero. The minimum dynamic
interfacial tension is limited ultimately by the strength and cohesion
of the monolayer ﬁlm. Eventually, the monolayer “collapses” and the
ﬁlm folds, buckles, deforms, cracks, etc. into either the subphase or the
air [19–25] (See Fig. 7). After this monolayer collapse, enough lung
surfactant must remain at the interface (or re-adsorb to the interface)
to respread and cover the expanding alveolar interface during
inspiration to restore the equilibrium surface tension and the low
dynamic surface tension.
A good lung surfactant therefore provides both a low equilibrium
surface tension and an even lower dynamic interfacial tension which
minimizes the work of breathing, stabilizes alveoli against atelectasis
during expiration, prevents excess liquid from accumulating in the
lung, and insures uniform inﬂation on inspiration [2–6,8,9,18]. Every
air-breathing animal with lungs has some form of lung surfactant,
often very similar in composition to human lung surfactant [17,26–
29]. This is why replacement surfactants for diseases associated with
surfactant deﬁciency or inhibition are harvested from cows (Sur-
vanta), calves (Infasurf) and pigs (Curosurf), the most common large
mammals raised for food in the US and Europe.
Although essential to breathing, lung surfactant [2,30–33] and
its importance in the development of neonatal respiratory distress
syndrome (NRDS; known as hyaline membrane disease at that
time) [8,34] was only begun to be appreciated in the late 1950s. In
NRDS, the lack of functional surfactant results in a progressive
failure of the lungs, which is manifested clinically by atelectasis,
decreased lung compliance (stiff lungs that require a greater pres-
sure differential to inﬂate), decreased functional residual capacity
(a measure of the amount of air left in the lungs after exhalation),
systemic hypoxia (oxygen starvation), and lung edema (bleeding in
the lungs) [2–4,8,30–32,34,35]. Only since the 1980s have infants
with NRDS been treated with replacement surfactants, which has
signiﬁcantly reduced neonatal mortality [9,36]. Surfactant-deﬁcient
infants typically have less than 5 mg/kg of LS in their lungs, while
typical healthy newborns have approximately 100 mg/kg. In 2002,
RDS affected an estimated 24,000 newborns in the US [9]. Surfac-
tant replacement is an expensive therapy; but it is cost-effective
relative to neonatal intensive care [37].
The ﬁrst clinically approved replacement lung surfactant, Exosurf,
was a synthetic mixture of dipalmitoylphosphatidylcholine (DPPC,
the major lipid component of native LS), hexadecanol, and the non-
ionic surfactant, tyloxapol. Although efﬁcacious, Exosurf does not
contain the lung surfactant speciﬁc proteins SP-B and SP-C or any
synthetic replacement peptide or protein [2]. Survanta, Curosurf and
Infasurf, currently the three most-used clinical surfactants in the US,
are organic solvent extracts from minced cow (Survanta) or pig
(Curosurf) lungs, or extracted with organic solvents from the aqueous
lavage of calf lung (Infasurf) [3,4]. The compositions of all four
clinically approved surfactants vary widely in lipid composition; there
still is no generally accepted lipid composition for a replacement
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replacement surfactants. As yet, there is no clinical surfactant
replacement that is as effective as whole, native lung surfactant
collected directly from lavage. Whole surfactant from lavage cannot
be used in human therapy due to water-soluble non-surfactant
proteins or infectious agents. The hydrophilic surfactant proteins SP-A
and SP-D can also be highly immunogenic if of animal origin. In
addition, while the lung surfactant speciﬁc proteins SP-B and SP-C are
essential to surfactant function, none of the animal extract surfactants
contains even half the levels of SP-B and SP-C as native surfactant due
to losses during organic solvent extraction and puriﬁcation [28].
Although there is no clinical surfactant that contains SP-A, this
hydrophilic protein makes up the largest fraction of LS protein, and is
believed to be important to LS adsorption as well as to lung host-
defense. SP-A is hydrophilic, so it cannot be harvested by organic
extraction.
One goal of research in LS is to develop an entirely synthetic
replacement surfactant that should reduce costs of NRDS treatment,
improve uniformity, and decrease the likelihood of contamination
with infectious agents [4,9]. However, as the myriad functions
and properties of lung surfactant are still being discovered and the
relationship between lung surfactant composition and function is
only slowly being revealed, there is likely a great deal of room
for improvement and new lung surfactant formulations are in the
pipeline.2. Surfactant inactivation
In certain cases, meconium aspiration syndrome being an exam-
ple, neonatal replacement surfactant therapy is less effective because
surfactant somehow loses the ability to reduce surface tension
and is said to be “inactivated” [3,9,13,38–42]. Surfactant inactivation
is a qualitative term for the inability of nominally sufﬁcient amounts
of surfactant to lower surface tension to levels necessary for lung
function [3,9]. Surfactant inactivation likely contributes to the
severity of acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS) in both children and adults. ARDS, the more acute
form of ALI, [43] was ﬁrst described in 1967 and shares many
symptoms with NRDS, although ARDS occurs as a rapid onset of
respiratory failure that can affect patients regardless of age [9,44–
47]. ARDS has an incidence of 150,000 cases per year (U.S.) and a
mortality rate of 30–40% [48–50]. The pathophysiology of ARDS
involves injury to the alveolar-capillary barrier, lung inﬂammation,
atelectasis, surfactant dysfunction, and intrapulmonary shunting.
The disorder typically appears within 12 to 24 h of an identiﬁable
clinical event such as gastric content aspiration, pneumonia, near-
drowning, toxic gas inhalation, or chest/lung trauma. In addition,
ARDSmay be associated with systemic processes such as sepsis, non-
thoracic trauma, acute pancreatitis, major surgery, multiple blood
transfusions, fat embolism, or shock. No speciﬁc therapy for ARDS
currently exists.
While ARDS has a more complicated pathology than the simple
absence of surfactant responsible for NRDS, ARDS shares many NRDS
symptoms such as diminished lung compliance, marked restriction of
functional lung volume, and hypoxemia. Hence, it was hoped ARDS
might respond favorably to surfactant replacement therapy. So far,
results have been mixed. Early clinical trials with the most effective
formulations used in NRDS provided modest and transient improve-
ment in adult ARDS patients [3,44,47,48,50,51], suggesting that ARDS
involves not only a lack of functional surfactant, but a mechanism of
inactivation that renders both endogenous and exogenous surfactant
ineffective. However, recent trials conductedwith pediatric acute lung
injury patients have shown signiﬁcant and positive impacts on
mortality after treatment with large doses of exogenous surfactant,
especially those containing SP-B and SP-C [52–55].There are many ways surfactant can be inactivated at various
points in the surfactant life cycle; from transcription and protein
translation, during multivesicular and lamellar body formation in the
type II cell [14–16,56], secretion into the alveolar liquid layer
(subphase) from the type II cells, transformation from lamellar bodies
to tubular myelin to membrane vesicles [3], re-uptake by type II cells
or macrophages, losses due to transport out of the alveoli to the
airways [3], or chemical degradation [9,41,57–59]. However, most of
these mechanisms should respond favorably to surfactant replace-
ment therapy [41]. Other abnormalities include modiﬁcation of the
phospholipid composition of LS, with decreased relative amounts of
phosphatidylcholine and phosphatidylglycerol and an increase in
cholesterol [60–62]. These biochemical abnormalities correlate with
the severity of respiratory failure [35]. One reason is that increased
cholesterol levels increase the minimum surface tension on mono-
layer compression [60,61,63,64]. Lipase [65] or oxidative [57,58,66]
damage to lipids or SP-B, C [58,67] may also contribute to inhibition.
These forms of inactivation are often slow to develop and are
permanent, and could also result in degradation of exogenous
surfactant over time.
However, in ARDS and ALI, inactivation is rapid. Understanding
how this inactivation occurs might explain why exogenous surfactant
does not have the dramatic effect in treating adult lung injuries that
are seen in treating premature infants with surfactant deﬁciency
[9,13,44–46,49,68–74]. In vivo, rapid surfactant inactivation in ARDS
patients often correlates with the presence of a variety of water-
soluble and surface-active substances normally absent from the
alveoli [3,44,68,72,75,76] including serum proteins, bile salts, lysoli-
pids, and other contaminants [46,68–70]. For example, reports of
the average albumin concentrations in the alveolar ﬂuid of ARDS
patients and healthy patients vary widely, but consistently suggest an
increase during ARDS: from 0.5 mg/mL for ARDS patients compared
to 0.03 mg/mL for healthy patients in one reference [72] to 25 mg/mL
for ARDS patients compared to 5 mg/mL for healthy patients in
another report [76]. Protein concentration in the alveolar ﬂuids of
ARDS patients has been shown to correlate with the severity of the
disease [77]. Da Silva et al. [62] have shown that serum proteins
leaking into a ventilated rat lung led to signiﬁcant decreases in
surfactant performance and lung compliance; the effects on the
surfactant were less when the lung was ﬂushed to remove blood and
reduce cholesterol. In vitro, there is an ARDS-like depression of LS
activity when serum proteins are added to a LS-covered interface [68–
70,74,78], LS is added to a serum-covered interface [13,79–84] or both
LS and serum proteins are presented simultaneously [85–87].
A common feature of these inhibitors of LS activity is a competing
surface activity; serum proteins, lysolipids, bile salts, etc. also
spontaneously adsorb to the air–water interface and lower the surface
tension. Surfactant inactivation is known to be strongly dependent on
both the species and concentration of inhibitor [13,42,68,88,89], as is
the surface activity. Unlike lung surfactants, which are insoluble in
saline, these inhibitors can exist both at the interface and in solution;
as a result, the surface tension does not drop appreciably on com-
pression of the interface [74,90,91]. Serumproteins, lysolipids and bile
salts have a surface pressure that is a logarithmic function of
concentration up to a saturation concentration, i.e. they form Gibbs-
type monolayers in many ways similar to simple detergents such as
sodium dodecyl sulfate (SDS) [74,91].
In Fig. 1, the surface pressures of ﬁbrinogen, albumin and IgG,
three serum proteins commonly implicated in surfactant inhibition,
are given as a function of concentration. Regardless of the protein or
the concentration beyond saturation, the surface pressure does not
increase to more than ∼25 mN/m for any serum protein at equi-
librium [91]. From Fig. 1, albumin and ﬁbrinogen reach the saturation
surface pressure at concentrations ∼.1 mg/mL, while IgG requires 100
times that concentration to reach saturation. This concentration
dependence of surface activity correlates with earlier work [92]
Fig. 1. Surface pressure π vs. protein concentration for bovine albumin, ﬁbrinogen and
IgG at 25±1 C in buffered saline; this behavior is consistent with the serum proteins
forming Gibbs-type monolayers. Fibrinogen and albumin exert a higher surface pres-
sure than IgG at all concentrations measured. Fibrinogen and albumin reach their
saturation concentrations at ∼.1–1.0 mg/mL, while the IgG concentration at saturation
is ∼10 mg/mL. The lower the concentration required to reach the saturation concen-
tration, themore surface-active is themolecule and the greater is its ability to inactivate
lung surfactant. However, the saturation surface pressure, Πsat, never goes much
beyond 20–25 mN/m for all surface-active serum proteins [91] and the surface pressure
does not increase signiﬁcantly on compression of the interface [74].
Fig. 2. Fixed amounts of the clinical lung surfactant Curosurf deposited within a
buffered subphase (24 °C) containing increasing concentrations of human serum. ● no
serum; ○ 0.4 μl serum/mL buffer; ▼ 0.8 μl serum/mL buffer; ∇ 1.7 μl serum/mL buffer.
The rate of increase in surface pressure after addition of Curosurf decreased below
∼20 mN/m (dotted line), and was proportional to the serum concentration. Above
∼20 mN/m, the rate of increase in surface pressure was similar to that of the serum-
free surfaces. The critical surface pressure at which the rates change is roughly equal to
the equilibrium surface pressure,Πeq, of a subphase containing serum, ∼20 mN/m (see
Fig. 1) [74,91] The data suggests that as the surfactant adsorbs, the surfactant com-
presses the serum components at the interface up to Πeq, at which the serum compo-
nents are squeezed-out from the interface back into the subphase. At higher serum
concentrations in the subphase, more serum is adsorbed to the interface (Fig. 1) and it
takes longer for surfactant to adsorb and raise the surface pressure toΠsat. This decrease
in the rate of adsorption with serum proteins can cause insufﬁcient surfactant to adsorb
to the interface in the time available during respiration.
Figure adapted from [13].
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Seeger et al. [92], albumin and ﬁbrinogen were shown to be potent
inhibitors requiring concentrations of just .1 and .01 mg/mL respec-
tively, while IgG had little effect even at 1 mg/mL. This relationship
between inhibitory power and surface activity appears to hold for
non-protein inhibitors as well. For lysopalmitoylphosphatidylcholine,
the surface pressure at the surface saturation concentration of
.004 mg/mL is 34 mN/m. Holm et al. showed that lysophosphatidyl-
choline is a more potent inhibitor than albumin [70,88]. Cockshutt has
shown that lysolipids increase the sensitivity of lung surfactants to
inhibition by serum proteins, even at very low concentrations [93],
consistent with the higher surface activity of the lysolipids.
3. Equilibrium vs kinetic effects
The equilibrium surface pressure, Πeq, is the negative derivative
of the Gibbs free energy, G, with respect to the interfacial area,
A : Πeq = − ∂G
.
∂A
 
n;T
[10]; therefore, the higher the equilibrium
surface pressure of a given surface-active species, the more thermo-
dynamically stable it is at the interface, and the more likely this
species will occupy the interface relative to another of lower equi-
librium surface pressure. For LS, Πeq (∼40 mN/m [13]) is much
higher than that of serum proteins (Πeq∼20 mN/m [74,91]) or
lysolecithins (Πeq∼30 mN/m). Therefore, LS should always be the
dominant species at the air–water interface under equilibrium
conditions.
However, in the expanding and contracting lung, it is doubtful if
interfacial equilibrium is ever established; hence, kinetics play a
dominant role in determining which species adsorbs to the air–water
interface. In vivo, LS likely never adsorbs to a pristine air–saline
interface, even though this is how almost all in vitro experiments with
LS begin. It is inevitable that other surface-active species (in addition
to LS) compete for the interface, or must be displaced from the
interface if they arrive ﬁrst. New interface is being created contin-
uously during the expansion of the alveoli that accompanies inspi-
ration, interface that must be coated with surfactant for properbreathing. Hence, if surfactant adsorption or spreading are slow rela-
tive to inhibitor adsorption, surfactant inactivation is a likely result
{Warriner, 2002 #20}.
For example, [9,13,41,42,68,70,74,79–85,94–96] serum proteins
can slow or even prevent LS from reaching the interface and achieving
an equilibrium distribution. Fig. 2 shows that the time necessary for
the clinical surfactant Curosurf to reach its equilibrium surface
pressure, Πeq of ∼42 mN/m, dramatically increases with increasing
concentrations of human serum in the subphase. What is curious is
that the rate of increase in Π is signiﬁcantly slowed only for surface
pressures below the serum Πeq of ∼20 mN/m and the slowing is
proportional to the serum concentration. However once the serum
Πeq was reached, further increases in Π up to the Πeq of the LS were
similar to that of the serum-free interfaces, and independent of serum
concentration [13]. Πeq of the LS (∼42 mN/m) was also independent
of the serum concentration, suggesting that the composition of the
adsorbed LS ﬁlm was independent of the serum presence or
concentration [13]. The shape of the adsorption curves suggest that
as the surfactant adsorbs, it ﬁrst concentrates the serum proteins at
the interface so that the surface pressure increases to the serumΠeq as
the adsorbing LS restricts the interface area available for the proteins.
This co-adsorption is consistent with ﬂuorescence images (Fig. 7) and
X-ray diffraction (Figs. 8,10) [79,80,82–84,97] that shows albumin
and LS coexist at an air–water interface. As surfactant adsorption
increases, the serum proteins must be displaced from the interface; as
the surface pressure increases above the serum Πeq, the serum
proteins are displaced from the interface and return to the subphase
[13,79,80,82–84,97]. At higher serum concentrations in the subphase,
the interfacial density of serum is also higher, and surfactant must
displace more protein to adsorb and raise the surface pressure. Once
the serum proteins are substantially removed from the interface by
the spreading LS, additional LS adsorbs more readily to a LS-covered
interface than to a serum protein-covered interface.
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to the subphase appears to never reach the interface and the surface
pressure remains near theΠeq of albumin (Fig. 3). The expansion and
compression isotherms of Survanta on an albumin-containing
subphase (Fig. 3b) do not show the characteristic features of Survanta
on a saline buffer (Fig. 3a); the isotherms are nearly identical to that of
albumin alone, showing that signiﬁcant amounts of Survanta have
not reached the interface (See Fig. 7). There is a small amount of
hysteresis in the isotherm of albumin suggesting that the albumin
changes its conformation, orientation or packing at the interface and
is less able to return to the saline subphase after compression {Dhar,
2009 #885}.4. LS bilayer organization and interactions in solution
Both endogenous and exogenous surfactants are inactivated in ALI
and ARDS; hence it is possible that serum proteins mix with or
otherwise alter LS bilayers in solution, thereby altering the adsorption
properties of the surfactant. Previous researchers have speculated that
there is a relationship between inhibition and surfactant microstruc-
ture [98–100] based on transmission electron microscopy of chem-
ically ﬁxed clinical lung surfactants. However, clinical surfactants are
N98% lipid and lipid aggregates are notoriously difﬁcult to ﬁx via the
conventional chemical techniques of glutaraldehyde/osmium tetrox-
ide ﬁxation and ethanol dehydration [14–16,56,101]. In comparison,
rapid freezing methods [102] provide more artifact-free images of
lipid bilayer samples in their hydrated state with no added chemical
ﬁxatives, while preserving both the distribution of the aggregates in
the original dispersion and the microstructure and bilayer organiza-
tion of the aggregates [87,102–121].
The chemical constituents of LS, disaturated dipalmitoylpho-
sphatidylcholine (DPPC), unsaturated phospholipids, and the two
hydrophobic LS speciﬁc proteins SP-B and SP-C [28], are effectively
insoluble in physiological saline. As a result, in aqueous solution the
fundamental building blocks of LS self-assembly are bilayers; these
bilayers further organize into more complex multilamellar liposome-
like aggregates 1–100 μm in diameter [87,102] (Fig. 4). Although the
basic structural unit is the bilayer, the bilayers within the clinical
surfactants are organized in quite different ways, likely due to the
differences in lipid composition, especially the fraction of saturated vs
unsaturated lipids, as well as the fraction of charged lipids and
cholesterol. Survanta forms the largest aggregates with the smallest
bilayer spacing, consistent with a highly ordered, likely gel phase
bilayer due to its high fractions of DPPC and palmitic acid [122–124].
Infasurf, with the smallest fraction of saturated lipids, forms very
open, multicompartment structures with a large amount of water
contained within the aggregate, indicative of highly ﬂuid and
ﬂuctuating bilayers. Curosurf, with intermediate saturated lipid frac-Fig. 3. (a) Normal isotherms of Survanta, a clinical lung surfactant, on a buffered saline subph
is indistinguishable from the albumin-only isotherm (red). Only albumin is adsorbed to thetions, forms aggregates that are intermediate between the structures
of Survanta and Curosurf (Fig. 4).
The bilayer–bilayer interactions that determine the equilibrium
bilayer d-spacing (or bilayer repeat spacing, which is a combination of
the bilayer thickness plus any water between the bilayers) are a
balance of van der Waals attraction [79,125–127] and a combination
of the Helfrich undulation repulsion [125,126,128–131] and electro-
static double-layer repulsion [87,119,120] (Eq. (14)). Small angle X-
ray scattering shows that when 10 kDa polyethylene glycol polymer is
added to Curosurf, the bilayer d-spacing decreases as shown in Fig. 5.
The same thing happens when sufﬁcient albumin is added to the
Curosurf suspension. This reduction in the d-spacing implies that
macromolecules such as 10 kDa PEG or albumin cannot enter the
aqueous spaces between the surfactant bilayers or incorporate within
the bilayers themselves [132–134]. This exclusion of the PEG or
albumin generates a concentration difference between the inside and
outside of the bilayer shells that make up the aggregate, which in turn,
generates an osmotic pressure difference that causes the water
between the bilayers of the aggregate to be expelled, and the bilayer
d-spacing to decrease so as to equalize the pressure between the
bilayers with the applied external osmotic pressure.
With no albumin or polymers in the solution, Curosurf has a
bilayer d-spacing of about 11 nm, which decreases to about 6 nm at
the highest PEG and/or albumin concentration, and hence, applied
osmotic pressure. As the bilayers come closer together, the inter-
bilayer repulsion increases, thereby increasing the internal pressure
between the bilayers. The functional form and characteristic decay
length of the inter-bilayer pressure is determined by the origin of the
interactions between the bilayers. If the electrostatic double-layer
repulsion (See 2nd term in Eq. (14)) dominates the bilayer–bilayer
interaction [132–134], the relationship between d-spacing and
applied pressure is exponential:
P = Po expðd = κ−1Þ; ð1Þ
κ−1 = ðεεokBTÞ=ðe2∑i z
2
i niÞ
 
1
=2 ð2Þ
with a characteristic decay length given by κ−1, the Debye length
(T is the absolute temperature, kB is Boltzmann's constant,
1.38054×10−23 Nm/K, zi is the valence of ionic species i, e is the
electron charge, 1.6021×10−19 C, ε0 is the permittivity of the
vacuum, 8.854×10−12 C2/N m2, and ε is the dielectric constant of
the solution (about 80 forwater) [135]. In practical units, κ−1 = :304ﬃ
I
p nm
for an aqueous buffer at 25 °C [127]. For the buffered, physiological
(150 mM NaCl, 2 mM CaCl2) saline used, the ionic strength,
I = 12∑z
2
i ρi≈:156moles=liter, which gives κ− 1∼ .77 nm (ρi is
the molar concentration of each ion and zi is the charge on that ion
[127]. ) Any additional counterions from the anionic lipids in thease. (b) Survanta on a 2 mg/ml albumin subphase. The Survanta plus albumin isotherm
interface under these conditions.
Fig. 4. Optical phase contrast (left column)and freeze-fractureelectron (right column)microscopy imagesofCurosurf (a, b), Infasurf (c, d) andSurvanta (e, f). a, c, e: Theoptical images showthat
all of the clinical surfactants consist of dispersed, small aggregates,with Survanta being the largest. c. Individual Curosurf aggregates aremultilamellar and typically had somevoid space between
bilayers and “pockets” of water within the aggregate. This is consistent with the small angle X-ray scattering that showed broad reﬂections indicative of poor correlations between the bilayers.
d. Infasurf aggregates had amulticompartment bilayer structure with densely packed interior vesicles and largewater pockets. The structures are similar to vesosomes, a vesicle in vesicle drug
delivery vehicle [114–116,220]. F. Survanta aggregateswere typically too large tobe imaged as individual particles in TEM.Herewe showthemultilamellar stacks ofwell-orderedbilayerswithin
the larger aggregates. There are no water pockets within the Survanta particles. The degree of organization of the aggregates scaled with the fraction of saturated phospholipids and fatty acids,
with Survanta being the most ordered and having the most saturated lipids, and Infasurf having the least ordered aggregates, with the highest unsaturated lipid and cholesterol fraction.
Figure adapted from [87].
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Fig. 5. Bilayer d-spacing measured by small angle X-ray scattering from dispersions of
Curosurf, Curosurf plus albumin and Curosurf plus albumin and 10 kDa PEG polymer as
a function of the osmotic pressure of polymer or polymer plus albumin. For osmotic
pressures greater than 103 dynes/cm2, the d-spacing decreases exponentially with
increasing osmotic pressure with a decay length of 0.72 nm, which is nearly identical to
the calculated Debye length of the solvent, κ−1=0.77 nm, conﬁrming that the bilayers
interaction is dominated by the electrostatic double-layer repulsion [132,133]. For
comparison to Figs. 4, 6, the osmotic pressure of 2 wt.% albumin is b103 dynes/cm2 and
the osmotic pressure of 5 wt.% 10 kDa PEG is ∼106 dynes/cm2 . The albumin and
polymer act primarily as osmotic agents that dehydrate the bilayers, conﬁrming that
albumin and polymer do not adsorb to or penetrate the surfactant aggregates.
Figure adapted from [87].
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reduce κ−1. Fig. 5 shows that the bilayer d-spacing for Curosurf is an
exponential function of the osmotic pressure with a characteristic
decay length of 0.72±0.2 nm, which is in excellent agreement with
the calculated Debye length. This behavior is typical for ﬂuid bilayers
with a signiﬁcant fraction of charged lipids stabilized by double-
layer repulsion [132–134]. Zeta-potentials of −10 to −15 mV have
been measured for other LS aggregates, which are also consistent
with electrostatic double-layer interactions [136].
Fig. 6 shows freeze-fracture TEM images of Curosurf and Infasurf
aggregates in a buffer solution containing 2 wt.% albumin (left) or
5 wt.% 10 kDa PEG (right). 2 wt.% albumin is more than sufﬁcient to
prevent LS adsorption, (Figs. 2,3,7) but does not alter the bilayer
organization within LS aggregates (compare to Fig. 4). Individual
albumin molecules adsorbed to or incorporated within the bilayers
would appear as 5–10 nm high bumps or pits on the bilayer surfaces
in freeze-fracture images [108]. However, the bilayers remain as
smooth as when there is no albumin in solution. This is consistent
with the SAXS data in Fig. 5 that shows that the primary effect of
albumin (even at much higher concentrations) is as an osmotic agent
that does not penetrate the aggregate. The osmotic pressure of a
2 mg/ml albumin solution is ∼103 dynes/cm2, which is not sufﬁcient
to alter the spacing of the Curosurf bilayers (See Fig. 5). While Infasurf,
Curosurf and Survanta have quite different compositions and micro-
structures, albumin does not adsorb to or alter the lamellar organization
of any of the clinical surfactants at concentrations at which surfactant
adsorption is inhibited.
In the presence of 5 wt.% 10 kDa PEG (or proportionately high
albumin concentrations), while there was little change in the average
aggregate size, the organization of the bilayers within the aggregates
was signiﬁcantly altered. The average bilayer spacing decreased
(as expected from the SAXS results) and there were no longer any
water-ﬁlled void spaces within the aggregates. The bilayers were
more ordered after exposure to PEG (compare to Fig. 4). For Infasurf in
5 wt.% 10 kDa PEG, instead of the vesicle within vesicle structure
common when there was no PEG (Fig. 4), the aggregates were much
more compact with concentric, parallel bilayers in onion-like struc-
tures [16,56]. The void spaces and water pockets were removed and
the interior compartments fused. However, Survanta, which consistedof compact bilayers with no void spaces even without PEG, did not
show signiﬁcant morphological changes caused by adding PEG at
5 wt.% (not shown).
5. Monolayer structure, organization and collapse
Alterations in the organization and structure of the monolayer
might also contribute to surfactant inactivation by serum proteins,
leading to lower collapse pressures, poor respreading, etc. When the
surfactant aggregates shown in Figs. 4, 6 contact the air–water
interface, the bilayers break down to form insoluble, Langmuir-type
monolayers andmultilayers (Fig. 7 and See Movie 1 in Supplementary
Materials). It appears that the aggregatesmust contact the interface to
undergo this conversion. If there is insufﬁcient area to spread on the
interface, the bilayer aggregates can partially fuse with the monolayer
or multilayer ﬁlm without undergoing complete conversion (bright
white patches in Fig. 7) [83,137]. Fig. 7 shows ﬂuorescence images of
Survanta (dopedwith 1 mol% of the ﬂuorescent dye, Texas Red-DHPE;
Molecular Probes, Eugene, OR) ﬁlms at the air–subphase interface.
The mottled black and gray textures in Fig. 7a are typical of a phase
separated lipid/protein monolayer (Fig. 7a; Π=18 mN/m); the
scattered, bright white patches are aggregates partially fused with
the interface. The gray patches, which contain a higher fraction of the
ﬂuorescent lipid dye, are disordered, ﬂuid lipid domains mainly
populated by unsaturated and anionic lipids and LS proteins
[4,20,22,138–140]. The dark gray patches, on the other hand, have
semi-crystalline order of the lipids molecules (See Fig. 8), which
excludes the ﬂuorescent lipid dye. This ordered phase contains most
of the DPPC, palmitic acid (PA) and other saturated lipids in LS
[123,124,137,140,141].
Surfactant adsorbs only up to the Πeq of 40–45 mN/m (Fig. 2); to
provide the necessary low tensions required for breathing, as the
available interfacial area is reduced in the alveolus during exhalation,
or on compression of the ﬁlm in a Langmuir trough (Fig. 7b), the
surface pressure increases to 65–70 mN/m as the available area per
molecule of LS decreases. At some point, the interfacial ﬁlm can no
longer support an increasing surface pressure and the ﬁlm fails or
“collapses” [22,24,25]. At collapse, the ﬁlm can no longer support the
imposed stresses and lung surfactant ﬁlms usually fail by buckling and
forming three-dimensional cracks and folds. Fig. 7b shows the cracks
and folds (arrows) at monolayer collapse in Survanta, which
determines themaximum surface pressure,Πmax that can be achieved
by the ﬁlm (Fig. 7b; Πmax=66 mN/m, surface tension of ∼6 mN/m)
[22,23,137]. The collapse mechanism [22,24,25,61,137,139,141–153]
and respreading of the monolayer ﬁlm are areas of intense interest,
but will not be examined in this review.
In contrast, when Survanta is deposited on a buffered subphase
containing 2 mg/ml albumin, the ﬂuorescence images are featureless
(Fig. 7c) or show isolated, out of focus bright spots (Fig. 7d) indicative
of Survanta aggregates in the subphase kept from reaching the
interface by the adsorbed albumin ﬁlm. It appears that the Survanta
does not undergo signiﬁcant conversion from bilayers to monolayers
and cannot unravel and expand to cover the interface unless the
surfactant particle comes into contact with the interface. Quantitative
comparisons shows that less surfactant adsorbs to the interface from
3.8 mg of Survanta deposited on an albumin subphase than from 30 μg
of Survanta deposited onto a clean subphase [83]. Albumin in the
subphase is roughly equivalent to lowering the surfactant concentra-
tion by a factor of 120! From the isotherms and the ﬂuorescence
images, the interface is essentially covered by albumin with very little
surfactant.
6. Lung surfactant interfacial organization
A second possibility underlying surfactant inactivation is that serum
proteins alter the monolayer organization, causing the surfactant to
Fig. 6. (Top row) Left: FF-TEM images of 10 mg/mL Curosurf with 2 wt.% bovine serum albumin (BSA) at room temperature. Right: 10 mg/mL Curosurf with 5 wt.% 10 kDa PEG.
(Bottom row) Left: FF-TEM images of 10 mg/mL Infasurf with 2 wt.% bovine serum albumin (BSA) at room temperature. Right: FF-TEM images of 10 mg/mL Infasurf with 5 wt.%
10 kDa PEG. For both surfactants, adding 2 wt.% albumin had little effect on the bilayer organization, even though this level of albumin completely inhibited adsorption. The bilayer
surfaces were smooth, indicating no adsorption or perturbation by the albumin. The microstructure of the aggregates was multilamellar with interior voids and water pockets and
poorly correlated bilayers as in Fig. 4. The size distribution of the aggregates was unchanged and ranged from 0.5 to 3 µm. However, PEG caused the Curosurf and Infasurf aggregates
to compact and dehydrate; there were no longer vesicles within vesicle structures, but rather onion-like multilamellar particles. The small vesicles appear to bind to and fuse with
the larger particles. The images and the SAXS (Fig. 5) are consistent with both albumin and PEG acting as a non-penetrating osmotic agents that dehydrate the surfactant aggregates
and cause closer bilayer spacing.
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to reduce surface tension. Table 1 summarizes the intermolecular d-
spacings, lattice parameters, area per chain, and coherence lengths of the
ordered portion of Survanta monolayers as a function of subphase
composition and surface pressure (Fig. 7a). Grazing incidence X-ray
diffraction (GIXD) provides information about the laterally ordered
(liquid condensed and solid phases) domains within the monolayer;
disordered (liquid expanded, ﬂuid or protein-covered) areas of the ﬁlm
do not diffract appreciably and are effectively invisible [154]. The
number and position of the Bragg peaks (Fig. 8) allow the determination
of the symmetry and repeat distances, d=2π/qxy, of the 2D lattice. The
sharper the peak, the better ordered the crystal, which is quantiﬁed by
the coherence length, Lxy, in the different lattice directions. The Bragg
rods give the molecular tilt; if a local maximum in the intensity of the
Bragg rod occurs for zN0, themolecules in themonolayer are tiltedwith
respect to the normal to the monolayer [154,155].
Fig. 8 shows the Bragg peaks (Fig. 8a) and Bragg rods (Fig. 8b) from
[154] monolayers of the LS, Survanta, as a function of surface pressure[97]. At Π=20 mN/m, two Bragg peaks are observed, with the inte-
grated intensity of the qxy=1.44 Å−1 or {1,0} peak, roughly twice that
of the qxy=1.48 Å−1 or {1,−1} peak, indicating a distorted hexagonal
lattice similar to DPPC and DPPC/palmitic acid mixtures under similar
conditions [123,124,137,141]. The lattice spacings (dxy=2π/qxy) are
d10=4.38 Å and d1-1=4.24 Å, corresponding to a distorted hexagonal
unit cell (see schematic diagram in Table 1) with axes a=b=4.95 Å
and γ=118°, similar to DPPC, and mixtures of DPPC and PA, [124].
This lattice spacing leads to a calculated area per hydrocarbon chain of
21.7 Å2. At 20 mN/m, the Bragg rod proﬁle (Fig. 8b) exhibits a local
maximum at qz=0.41 Å−1, indicating that the lipid molecules are
tilted relative to the surface normal [137].
At Π=30 mN/m, the two Bragg peaks shift to qxy=1.47 Å−1 and
qxy=1.49 Å−1 indicating a less tilted lattice. The local maximum in
the Bragg rod moves closer to zero (qz=0.23 Å−1) conﬁrming the
reduction in lipid tilt. At 40 mN/m, the single peak at qxy=1.49 Å−1
indicates a transition to an untilted hexagonal lattice (a=b,
α=120°) with d10=4.21 Å and ja j = jb j = 2d10 =
ﬃﬃﬃ
3
p
= 4:86A˚ .
Fig. 7. Fluorescence images of 800 μg Survanta spread at varying subphase compositions. Images are 180 μm by 250 μm. The left column is for each subphase composition at
Π=18 mN/m (a, c, e, and g) and the right column is for each subphase at the maximum surface pressure reached during the cycle (66, 40, 31, and 38 mN/m, respectively for b, d, f,
and h). Row 1—Survanta on a clean, buffered subphase. (a) shows themottled texture typical of a phase separated lipid/proteinmonolayer. Themottled texture is found at all surface
pressures from 0 to collapse. (b) Arrows denote cracks where material is forced from the interface at the collapse plateau at 66 mN/m. Row 2—Survanta on buffer containing 2 mg/
mL albumin. (c) At low surface pressure, no ﬂuorescence is visible showing that the albumin prevents Survanta from adsorbing to the interface. (d) After several expansion and
compression cycles (see Fig. 1b), Survanta comes close to the interface, but does not spread due to the albumin ﬁlm at the interface. (Compare to e–h). Row 3— (e) During the ﬁrst
cycle for Survanta spread on buffer containing 2 mg/mL albumin and 0.12 wt.% PEG, small areas of the interface are starting to become covered with Survanta. (f) The Survanta
monolayer begins to displace the albumin (arrow). Row 4— (g) By the third expansion-compression cycle for Survanta spread on buffer containing 2 mg/mL albumin and 0.12 wt.%
PEG larger areas have a morphology similar to Survanta on a clean interface (Row 1, a,b) in coexistence with areas similar to albumin (Row 2, c, d). The dotted white lines denote the
borders between the two regions 0.12 wt.% PEG is not sufﬁcient to allow for sufﬁcient Survanta adsorption to completely displace the albumin (See Fig. 3). For ∼1 wt.% PEG, the
images are identical to Row 1 for all cycles (not shown).
Figure adapted from [83].
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Fig. 8. Bragg peaks (a) and Bragg rods (b) from GIXD scans of 200 μg Survanta spread onto a saline buffer subphase. (a) Bragg peaks at 20–50 mN/m. The points indicate instrument
data, the black curve is the overall ﬁt and the blue curves are ﬁts of the individual peaks. The packing changes from distorted hexagonal to hexagonal at 40 mN/m (see schematic in
Table 1). A second unknown phase is visible at 1.42 Å−1 at higher surface pressures. (b) Bragg rods at 20–50 mN/m. The local maximum of the Bragg rod proﬁle shifts left with
increasing surface pressure indicating a reduction in tilt of themolecules relative to the normal; themolecules are normal to the interface forΠ≥40 mN/m as indicated by the lack of
a local maximum for zN0. The lattice spacings and details of the molecular ordering are given in Table 1.
Figure adapted from [97].
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molecules are normal to the interface. Increasing the surface pressure
to 50 mN/m results in only a slight right shift of the main to peak to
qxy=1.50 Å−1; the Bragg rods again indicate that the molecules areTable 1
a The ﬁrst row for a PEG subphase at 40 mN/m is 200 μg Survanta while the second is 600 μg
per chain as a function of subphase composition and surface pressure. Phase 1 is the dom
hexagonal lattice (a=b, γ=120°) with increasing surface pressure. The approximate molec
is the area per chain (20.2 A2 is the minimum area per chain for orientations normal to the
full widths at half maximum height (FWHM) relative to the instrument resolution FWHMre
[FWHMmeas(qxy)2−FWHMresol(qxy)2]1/2 and the Scherrer formula deﬁnes the coherence leuntilted. Survanta ﬁlms are more compact than DPPC ﬁlms; a pure
DPPC ﬁlm at Π=40 mN/m shows two Bragg peaks at qxy=1.38 Å−1
and qxy=1.46 Å−1 indicating that the DPPC lattice is still tilted
[124,156]. The solid phase domains in Curosurf and Infasurf have.Survanta d-spacings, unit cell parameters (see inset ﬁgure), coherence length and area
inant phase and transitions from a distorted hexagonal lattice (a=b, γ ≠ 120°) to a
ular tilt relative to the normal to the interface is given by t=cos(20.2/AC), in which Ac
interface in a hexagonal lattice). The coherence lengths are determined from the peak
sol(qxy)=0.0084 Å−1. The intrinsic FWHM can be obtained from: FWHMinstrinsic(qxy)=
ngth: Lxy≈0.9[2π/FWHMintrinsic(qxy)] [219].
Fig. 9. The electron density proﬁles calculated from X-ray reﬂectivity data normalized
by the subphase electron density, for 200 μg Survanta spread on the control subphase.
Increasing Z moves from the air (Z=0) through the interface and into the subphase.
With increasing surface pressure, the density of the headgroupmaximum increases, the
width of the headgroup region decreases and the location of the headgroup maximum
shifts right, consistent with the GIXD data in Fig. 8 that shows a steady decrease in the
molecular tilt with increasing surface pressure.
Figure adapted from [97].
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DPPC is different, the surface pressure dependence of the lattice spacing
and the tilt are also different [123,124,137,141].
X-ray reﬂectivity (XR) provides the complementary laterally
averaged electron density proﬁle normal to the interface. Unlike
GIXD, XR is sensitive to all materials at the interface regardless of local
order. Fig. 9 shows the electron density proﬁles of adsorbed Survanta
ﬁlms, normalized by the subphase electron density (ρ(Z)/ρsub) [157–
159] . For LS ﬁlms, the electron density begins at 0 on the air side of
the interface (Z=0), rises sharply through the tail region, and reaches
amaximum at the headgroup region at Z∼30 Å before quickly decaying
to the subphase electron density (ρ(Z)/ρsub=1) at Z∼42 Å. The density
of the headgroup maximum increases (1.17 to 1.22) and the width of
the maximum decreases and shifts to the right with increasing surface
pressure, indicating a reduction in the tilt of the tails, consistentwith the
Bragg rods in Fig. 8 and previous XR of DPPC monolayers [160].
When Survanta is adsorbed to an interface from a subphase
containing albumin, both GIXD and XR conﬁrm that albumin or LS
coexist at the interface, consistent with the ﬂuorescence images in
Fig. 7. At Π=20 mN/m, different areas of the interface showed
dramatically different scattering patterns. Region 1 (Fig. 10a, ﬁrst
panel) shows no diffraction peaks, consistent with a disordered
albumin ﬁlm at the interface. However, Region 2 (Fig. 10a, second
panel), which was obtained by simply moving the interface
horizontally by several mm in the direction perpendicular to the X-
ray beam, shows Bragg peaks consistent with a distorted hexagonal
lattice with the {1,0} reﬂection at qxy=1.39 Å−1 and the {1,−1}
reﬂection at qxy=1.47 Å−1. The lattice is slightly expanded compared
to Survanta at 20 mN/m with a=b=5.04 Å and γ=116°. The Bragg
rods exhibit a local maximum at qz=0.57 Å−1, indicating a greater
molecular tilt than Survanta on the control subphase (Fig. 8b). While
the isotherm (Fig. 1b) and ﬂuorescence images (Fig. 7) [82–84]
indicate that the albumin dominates the interface under these
conditions, the distorted hexagonal lattice demonstrates that some
ordered domains of Survanta have broken through to the interface.
Compressing the ﬁlm in the trough increased the surface pressure
only to 28 mN/m (see Fig. 1b), which caused the two Survanta peaks
to shift to qxy=1.44 Å−1 and qxy=1.48 Å−1 , corresponding to a less
tilted lattice. While there are subtle changes in the Survanta tilt and
lattice spacing on albumin-containing subphases, the general features
are unchanged [123,124,137,141,161]; it appears as if the albumin
were slightly lowering the effective surface pressure. The last panel
in Fig. 10 shows GIXD scans after two additional compression–expansion cycles; the Bragg peaks disappear, indicating that no
ordered domains of Survanta remain at the interface. From the
minimal changes in the lattice spacing and tilt of the Survanta, there is
minimal mixing of the albumin ﬁlm with the ordered fraction of the LS
ﬁlm at the interface.
XR electron density proﬁles conﬁrm the albumin–LS coexistence at
the interface. For albumin alone, the electron density at the interface
increases more sharply than does Survanta on (Fig. 11), reaching a
maximum ρ/ρsub=1.25 at Z=15 Å. Other globular proteins such as
β-lactoglobulin have a similar maximum electron density (ρ/
ρsub=1.20) [162]. Unlike the electron density proﬁles for Survanta
(Fig. 9), ρ/ρsub is signiﬁcantly greater than 1 for 50bZb100 Å,
suggesting a second layer of albumin [97], which is a prolate spheroid
of dimensions 40×40×140 Å [163], with the albumin long axis parallel
to the interface. Both neutron reﬂectivity [163] and ellipsometry [164]
also indicate a dense, closely packed albumin monolayer with a less
dense second layer.
The electron density (Fig. 11) corresponding to Region 1 and
Region 2 (deﬁned in Fig. 10), are qualitatively similar to albumin even
though GIXD showed small patches of ordered Survanta in Region 2.
However, the electron density of themixed Survanta/albumin ﬁlms in
both Region 1 and Region 2 decreased more quickly with increasing z
than the albumin ﬁlm. This suggests that Survanta has displaced the
second layer of albumin (Fig. 7c,d). In contrast, the electron density of
the mixed Survanta–albumin ﬁlm at 28 mN/m, the highest surface
pressure that could be achieved for the duration of the XR experiment,
is very similar to that of Survanta on the control buffer at 30 mN/m.
The GIXD curve of Survanta–albumin at 28 mN/m (Fig. 4) shows
diffraction peaks, conﬁrming that Survanta is at the interface. The
ratio of Survanta to albumin at the interface apparently increases with
increasing surface pressure. However, the ﬁlm is still “inhibited” by
albumin; the isotherms (Fig. 3) shows that the maximum surface
pressure does not increase above 35 mN/m even after compression to
the smallest trough area, suggesting that the Survanta never com-
pletely displaces the albumin.
At all surface pressures, 10 kDa PEG in the subphase induces
minimal changes in the Survanta Bragg peaks and Bragg rods (Table 1)
[97], indicating that PEG, like albumin, does not signiﬁcantly modify
the molecular lattice of the ordered domains of the surfactant.
Additionally, Table 1 shows that at a speciﬁc surface pressure
(Π=40mN/m)and subphase condition (5wt.%PEG), different amounts
of Survanta (200 μg and 600 μg) yield nearly identical lattice parameters.
This conﬁrms that at a given surface pressure, there is a unique, ﬁxed area
per molecule [83] for a given temperature; the surface density is not a
function of the subphase concentration, but only of the surface pressure and
temperature.
7. Kinetically hindered equilibrium and analogies to colloid
stability
The equilibrium spreading pressure, collapse pressure, LS aggregate
sizes and shapes in solution, the bilayer d-spacing and the monolayer
lattice spacing and tilt are not affected by albumin or serum at
concentrations that inactivate LS performance [97]. Hence, this
mechanismof inactivation does not involve alterations to the surfactant
bilayer or monolayer. However, both albumin and LS prefer to occupy
the air–water interface, resulting in a competition for the available area.
Because of its nanometer size, albumin diffuses much faster thanmulti-
micron bilayer aggregates of LS (Figs. 4, 6). The Stokes–Einstein
diffusivity, DSE=kBT/6πηsa, shows that an albumin molecule 2 nm in
radius, a, should diffuse 1000 times faster than a surfactant aggregate of
radius 2 μm in saline with a bulk viscosity ηs. Hence, albumin and the
other serum proteins will almost inevitably beat LS aggregates in the
race to anuncoated interface [74,165]. In both the expanding alveolus in
the lung and the Langmuir trough, new air–water interface is
continuously being created for this competitive adsorption. In addition
Fig. 10. Bragg peaks (a) and Bragg rods (b) from GIXD scans of 600 μg Survanta spread onto a saline buffer subphase containing 2 mg/mL albumin. (a) Bragg Peaks at 20–30 mN/m.
The points indicate the diffraction data, the black curve is the overall ﬁt and the blue curves are ﬁts of the individual peaks. The ﬁrst two panels show different regions of the ﬁlm at
the same surface pressure. Surface pressures higher than 28 mN/m cannot be sustained due to the presence of albumin. The distorted hexagonal lattice is slightly shifted compared
to Survanta on a saline buffered subphase (See Table 1 for details). The last panel shows a GIXD scan at 20 mN/m after two additional cycles; the Survanta peaks are no longer
present. (b) Bragg rods at 20–28 mN/m for scans containing Survanta peaks. At each surface pressure, a local maximum occurs for zN0 and at a given surface pressure the molecular
tilt is somewhat greater than on the control subphase.
Figure adapted from [97].
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whatever part of the interface it already occupies in order to lower the
surface tension so that proper lung function occurs. From the isothermsFig. 11. The electron density proﬁles, normalized by the subphase electron density from
X-ray reﬂectivity measurements for 600 μg Survanta spread on a saline buffer subphase
containing 2 mg/mL albumin. No Survanta is present for the albumin-only subphase
data. Region 1 and Region 2 are the same areas as the GIXD data in Fig. 10. For Survanta–
albumin mixtures at 20 mN/m, the electron density proﬁle is similar to albumin for
both Region 1 and Region 2, while for 28 mN/m, the electron density proﬁle is similar to
Survanta (Fig. 9).
Figure adapted from [97].(Fig. 3b), ﬂuorescence images (Fig. 7) and X-ray (Figs. 8–10), if a
signiﬁcant fraction of the interface is covered by albumin or serum
proteins, sufﬁcient LS cannot adsorb to the interface to raise the surface
pressure to the levels needed for proper lung function for a given
compression (ΠN60 mN/m, surface tension b10 mN/m).
Clearly, there is something about the presence of serum proteins at
the interface that inhibits lung surfactant adsorption [9,13,42,68–
70,74,88,96,166]. To adsorb, LS must ﬁrst clean an area of interface by
pushing the albumin aside, which reduces the overall driving force for
LS adsorption [165]. Instead of increasing the surface pressure from
zero at a clean interface to the ∼40 mN/m equilibrium spreading
pressure of LS, albumin already had increased the surface pressure to
∼20 mN/m. This change in the driving force likely leads to changes in
the desorption of albumin and the adsorption–desorption equilibrium
for LS [165].
However, from theﬂuorescence images and isotherms, LS oftendoes
not even reach the interface, there appears to be a long-range repulsion
inhibiting LS transport to the interface. The isoelectric point of albumin
is 5.2, and hence albumin, like LS, is negatively charged at physiological
pH, which can induce an electrostatic energy barrier to adsorption
[80,96], preventing LS from reaching the interface and converting from
bilayers to a surface-activeﬁlm [42]. This energybarrier to LS adsorption
is reminiscent of the energy barriers that stabilize colloidal dispersions
and prevents them from coagulating [9,13,42,80,83,84,95,96]. Colloidal
dispersions should coagulate at equilibrium due to strong, short range
interactions, yet they somehow remain stable for years and even
decades [79,127,135,167,168].
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albumin, was ﬁrst exploited for the preparation of ink in ancient Egypt
and China as early as 2500 BC [169]. By mixing the soot from lamps
with a solution of proteins (casein from milk, egg albumin, or gum
Arabic), the ink could be dried and stored.When ﬂuid inkwas needed,
the dried ink was dipped into water, and the soot particles coated by
the proteins spontaneously redispersed and the ink was ready for use.
Fast redispersion is a characteristic of colloids that are stabilized by
proteins and other biopolymers [169].
The famousBritish chemical physicist,Michael Faraday, reported the
ﬁrst scientiﬁc study of the effects of albumin and other proteins on
colloid stability in 1857 [170,171]. In the absence of protein, a gold sol
could be induced to aggregate by the addition of sodium chloride;
aggregation was not observed when protein was present. Some of
Faraday's original gold colloids remain dispersed and apparently stable
today [171]. Richard A. Zsigmondy, who won the Nobel Prize in
Chemistry in 1925, quantiﬁed the relative effects of different biopoly-
mers in preventing the coagulation of a gold sol by a ﬁxed concentration
of sodium chloride, which he termed the “gold number” [172]. The gold
number of a protein was deﬁned as the amount inmilligrams of protein
which, when added to 10 ml of a gold sol, just prevents coagulation on
the addition of 1 ml of a 10% salt (NaCl) solution. For gelatin, the gold
number was ∼0.01; for albumin, ∼0.1, showing that albumin and other
soluble, surface-active proteins were quite effective at stabilizing a gold
sol against coagulation [169]. However, quantifying and predicting the
stabilizing effects of albumin and the destabilizing effects of electrolytes
on colloids required another 80 years of research.
The ﬁrst step toward understanding the mechanisms behind
colloid stability was the derivation by Smoluchowski (1917) of
diffusion-limited coagulation [173], which Fuchs (1934) extended
to show that the coagulation rate slowed in the presence of an
repulsive inter-particle potential, Φ [174]. The ﬂux/area, − J=dГ/
dt, (Γ is the interfacial concentration in molecules/unit area) to an
interface located at x=0, is proportional to a friction factor, DSE/
kBT, which is in turn proportional to the diffusivity of the colloidal
particles, DSE, (here the lung surfactant aggregates, Figs. 4, 6). The
driving force, in general, is the product of the local bilayer aggregate
concentration, C, and the gradient in chemical potential∇μ:
− dΓ
dt
= J = − DSE
kBT
C∇μ : ð3Þ
The normal chemical potential is altered by the inter-particle
potential, Φ(x):
μ = μo + kBT lnC + ΦðxÞ: ð4Þ
Combining Eqs. (3), (4) leads to a generalized diffusion equation:
−J = DSE
dC
dx
+
C
kBT
dΦ
dx
 
: ð5Þ
The ﬁrst term on the right side of Eq. (5) is the normal diffusive
ﬂux, which is usually called Fick's First Law of Diffusion [175]. At
steady state, the ﬂux/area, J, in Eq. (5) is constant, and Eq. (5) can be
integrated by multiplying both sides by exp(Φ/kBT):
−J
DSE
exp
Φ
kBT
 
=
dC
dx
+
C
kBT
dΦ
dx
 
exp
Φ
kBT
 
=
d
dx
C exp
Φ
kBT
  
ð6Þ
and integrated as follows:
∫
CB
0
d C exp
Φ
kBT
  
= − J
DSE
∫
∞
0
exp
Φ
kBT
 
dx: ð7ÞThe simpliﬁed limits of integration are such that the LS aggregate
concentration is zero anytime a surfactant aggregate gets to the
interface at x=0, (the surfactant aggregate converts to monolayer
form, making C=0 at x=0), and the concentration reaches the bulk
surfactant solution concentration, C=CB, and the potential, Φ→0, as
x→∞. This gives:
C exp
Φ
kBT
  CB
0
= CB = −
J
DSE
∫
∞
0
exp
Φ
kBT
 
dx ð8Þ
The integral on the right-hand side of Eq. (8) is approximated by
noting that the integral is dominated by the value of Φ at its
maximum, Φmax, and the potential can be expanded in a Taylor series
about the maximum [176]:
Φ≅Φmax +
dΦmax
dx
ðx−xmaxÞ +
d2Φmax
dx2
ðx−xmaxÞ2
2
 !
+ … ð9Þ
dΦmax/dx=0 at Φmax. Combining Eqs. (8) and (9) gives:
CB = −
J
DSE
exp
Φmax
kBT
∫
∞
0
exp
d2Φmax
dx2
ðx−xmaxÞ2
2
 
kBT
2
4
3
5dx: ð10Þ
In Eq. (10), the integrand is simply that of a Gaussian and gives:
CB = −
J
DSE
π0:5
2p
exp
Φmax
kBT
p2 =
−d2Φmax
dx2
,
2kBT
ð11Þ
p is a constant that reﬂects the curvature at the potential maximum.
Rearranging Eq. (11),
J = −2pDSECB
π0:5
exp
−Φmax
kBT
= −DeffCB exp
−Φmax
kBT
: ð12Þ
Deff is an effective diffusion coefﬁcient. Eq. (12) shows that the ﬂux
to the interface is slowed exponentially by an energy barrier of height
Φmax/kBT. For Φmax/kBT∼5, the ﬂux is reduced by 150 times; for
Φmax/kBT∼10, the ﬂux to the interface is reduced by a factor of
20,000! In Fig. 2, the time it takes for Curosurf to increase the surface
pressure to N20 mN/m increases from about 2 s for a clean interface
to more than 250 s for a serum-covered interface for the same bulk
concentration of Curosurf, consistent with Eq. (12) and Φmax/kBT∼5.
Doubling the bulk surfactant concentration does not have nearly the
effect of reducing the potential barrier by 50%, for instance, from
10 kBT to 5 kBT. This is likely why simply increasing the surfactant
concentration does not lead to a signiﬁcant improvement in surfactant
adsorption in the presence of albumin or other charged, surface-active
inhibitors. To stabilize colloidal particles indeﬁnitely (from coagula-
tion in 10 s to more than one year) against equilibrium aggregation,
the energy barrier height need only be ∼15 kBT [169]. For the
relatively fast cycles of expansion and compression under normal
breathing (of order seconds), the energy barrier does not have to be
very high to effectively inhibit surfactant adsorption.
From Eq. (12), the ratio of the diffusion-limited (Φ=0) ﬂux, Jo, to
the actual ﬂux, J, at a ﬁxed bulk concentration is proportional to the
exponential of the potential maximum, Φmax [176]:
Jo
J
∝ exp Φmax
kBT
 
: ð13Þ
To enhance surfactant adsorption in the presence of proteins, it is
essential to know how to manipulate Φ. At the time Eq. (8) was
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particles (and LS aggregates), nor the functional form of the repulsion
or attraction were known. In the 1940s, Derjaguin, Landau, [167]
Verwey, and Overbeek [168] (DLVO) combined the van der Waals/
London dispersion attraction [177] with double-layer electrostatic
repulsion [135] to give the functional form of Φ between two spheres
of radius, a, at a separation, r, surface potential, ψs, and ion concen-
tration, ni, via the Debye length, κ−1:
Φ = 32πεεo
kBT
ez
 2
a tanh2
ezψs
4kBT
 
expð−κrÞ− aAH
12r
ð14Þ
AH is the Hamaker constant that determines the magnitude of the
attractive dispersion forces [177]. The magnitude and range of the
DLVO potential can be most easily be changed by changing the ionic
strength of the solution, which decreases both κ−1 andΦmax (and to a
lesser extent, AH [127]). Both Faraday and Zgismondy de-stabilized
their gold sols by adding NaCl [169,170]. If the negatively charged
albumin and serum proteins act to induce a DLVO-type energy barrier
to LS adsorption, just as albumin adsorbed to gold colloids inhibitsFig. 12. Cyclic isotherms of Survanta and albumin on a buffered subphase (0.2 mM
NaHCO3 and pH=7) containing varying NaCl and CaCl2 concentrations. (a) 800 μg
Survanta deposited onto a subphase containing varying NaCl concentrations. For all
plots, the solid symbol denotes the surface pressure after adsorption before beginning
the ﬁrst compression cycle. The ﬁrst compression, ﬁrst expansion and second
compression are shown for all three isotherms. □ 1000 mM NaCl subphase; ○
150 mM NaCl subphase; △ 0 mM NaCl subphase. Increasing NaCl concentration
increases the equilibrium surface pressure, the minimum surface pressure on
expansion and promotes re-adsorption of collapsed material. (b) Fourth cycle
isotherms of 2 mg/mL albumin on a buffered subphase (0.2 mM NaHCO3 and
pH=7) containing varying concentrations of electrolytes. No Survanta has been
deposited. □ 1000 mM NaCl subphase; ○ 150 mM NaCl subphase; △ 0 mM NaCl
subphase; ∇ 150 mM NaCl, 20 mM CaCl2 subphase. The albumin isotherm is
independent of the subphase electrolyte concentration indicating that the albumin
adsorption and surface activity are unchanged over the range studied.coagulation, we expect that adding NaCl should promote LS
adsorption.
Fig. 12a shows the effect of varying the NaCl concentration on the
adsorption of 800 µg of Survanta on a buffered subphase (0.2 mM
NaHCO3, pH∼7) with no albumin present. The respective Debye
lengths are ∼21 nm for the subphase with no added salt, .78 nm for
the 150 mM NaCl and .304 nm for 1000 mM salt at 25 °C. The
minimum surface pressure after adsorption, but before compression,
more than doubled from 14 mN/m for no salt, to 29 mN/m for
1000 mM NaCl. On the ﬁrst compression, a characteristic shoulder at
∼45 mN/m and collapse plateau at ∼65 mN/m are visible. On
expansion, the minimum surface pressure drops to ∼0 mN/m on
the subphase with no NaCl, but is ∼15 mN/m on the 1000 mM NaCl
subphase. The length of the characteristic shoulder and collapse
plateaus are roughly the same for the 150 and 1000 mN NaCl
subphases on the ﬁrst and second compressions; for the subphase
with no NaCl, the shoulder and the collapse plateau aremuch reduced.
These isotherms show that higher NaCl concentrations in the
subphase promote Survanta adsorption and respreading, even to a
clean interface [178]. This should not be surprising since both the
surfactant aggregates and monolayer contain a signiﬁcant fraction of
anionic lipids, which should lead to a DLVO repulsion even between
the surfactant aggregates and the surfactant ﬁlm, which is decreased
by higher electrolyte concentrations.
On the other hand, Fig. 12b shows that increasing the electrolyte
concentration has little effect on the cyclic isotherms of 2 mg/ml
albumin with no LS present. All the curves reach a maximum surface
pressure of ∼33 mN/m on compression and a minimum surface
pressure of ∼ 11 mN/m on expansion. Hence, the electrolyte does not
lead to precipitation of the albumin or signiﬁcant changes in the
albumin adsorbed to the interface.
Fig. 13 shows the dramatic effects on adsorption as the NaCl
concentration is increased when 800 µg of Survanta was deposited on
a buffered subphase containing 2 mg/ml albumin. For NaCl concen-
trations up to 333 mM, the compression isotherms were indistin-
guishable and showed virtually no Survanta adsorption; they were
identical to the albumin-only compression isotherms in Fig. 12b.
However, increasing the NaCl to 450 mM restored the characteristic
shoulder and collapse plateau (Fig. 12a) typical of Survanta adsorbing
to an albumin-free interface, although it required a greater compres-
sion (smaller trough area) to reach these plateaus. This is characteristic
of slower than diffusion-limited adsorption. Further increases in NaClFig. 13. Fourth cycle compression isotherms of 800 μg Survanta on a buffered subphase
(0.2 mM NaHCO3 and pH=7) containing varying NaCl concentrations and/or albumin
(2 mg/mL when present). □ Survanta on a 150 mM NaCl subphase; ○ Survanta–
albumin on a 150 mM NaCl subphase; △ Survanta–albumin on a 333 mM NaCl
subphase;∇ Survanta–albumin on a 450 mM NaCl subphase; ◊ Survanta–albumin on a
600 mM NaCl subphase; ⌂ Survanta–albumin on a 1000 mM NaCl subphase. A
subphase containing 1000 mM NaCl is necessary to completely reverse the albumin
inhibition and restore surfactant adsorption.
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areas, implying greater adsorption; for 1000 mM NaCl, the compres-
sion isotherm with albumin in the subphase occurs at an even greater
trough area at a given surface pressure than for Survanta adsorption on
an albumin-free, 150 mMNaCl subphase. As the relationship between
surface pressure and area/molecule is ﬁxed for Survanta (See X-ray
results in Table 1), this increase in trough area at a given surface
pressure shows that more Survanta is adsorbing to the interface as the
electrolyte concentration is increased. The added NaCl decreases κ−1,
which causes a decrease inΦmax and an increase in the diffusive ﬂux of
surfactant to the interface, consistent with Eqs. (12)–(14).
While the qualitative enhancement of adsorption is obvious from
Fig. 13, it is difﬁcult to directly calculate the theoretical enhancement
of adsorption due to changes in electrolyte concentration from
Eqs. (12)–(14) as many of the parameters (ψs, AH, a) are unknown.
However, it is much easier to show how adsorption should scale with
the valence of the ions in solution. One of the surprising early
generalizations in colloid science (1880–1900) was that the critical
electrolyte concentration required to ﬂocculate (CFC) a variety of
positive and negative colloids was essentially independent of the
chemical or physical details of the colloid and the electrolyte, but
decreased as z−6, (z is the valence of the ion opposite in charge to the
colloid), which is known as the Schulze–Hardy rule [135,179,180].
Starting with the DLVO potential, Eq. (14), rapid, diffusion-limited
coagulation or ﬂocculation should occur at an electrolyte concentra-
tion (called the critical ﬂocculation concentration or CFC) at which
Φmax=dΦ/dr=0, that occurs when the separation between spheres,
r=κ−1:
CFC =
98479ðεεokBTÞ3
z6e6
kBT
AH
 2
tanh4
ezψs
4kBT
 
: ð15Þ
For ezψs/4 kBTN1, in the limit of large surface potentials, ψs,
tanh4 ezψs4kBT
 
≈1 and the CFC∝z−6, which successfully explained the
Schulze–Hardy rule [135], and was one of the ﬁrst important
validations of the DLVO theory.
Fig. 14 shows that signiﬁcantly lower levels of CaCl2 restore
surfactant adsorption in the presence of albumin. For each NaCl
concentration, the Schulze–Hardy rule (CFC proportional to z−6) wasFig. 14. The fourth cycle compression isotherms of 800 μg lipid dispersion on a buffered
saline subphase (0.2 mM NaHCO3 and pH=7) containing 2 mg/mL albumin and
varying electrolyte concentrations. □ 150 mM NaCl subphase; ○ 333 mM NaCl
subphase; △ 450 mM NaCl subphase; ∇ 600 mM NaCl subphase; ◊ 1000 mM NaCl; ■
0 mM CaCl2, 150 mMNaCl subphase;● 2 mM CaCl2, 150 mMNaCl subphase;▲ 3.5 mM
CaCl2, 150 mM NaCl subphase; ▼ 5 mM CaCl2, 150 mM NaCl subphase; ♦ 10 mM CaCl2,
150 mM NaCl subphase. For each NaCl concentration, the theoretical CaCl2 concentra-
tion according to the Schulze–Hardy/DLVO scaling (Eq. (13)) is given. The agreement
between theory and experiment is excellent.
Figure adapted from [79].used to compare the isotherm with a functionally equivalent amount
of CaCl2 in the subphase. To make the comparisons physiologically
relevant, 150 mM NaCl was taken as a baseline electrolyte concen-
tration (e.g. for 1000 mM total NaCl, the equivalent CaCl2 concentra-
tion for 850 mM NaCl is 2− 6 ⁎ 850=13.3 mM). The CaCl2
concentrations relative to the NaCl concentrations (above 150 mM)
to restore surfactant adsorption are in the ratio 2−(6.4±0.1), in
excellent agreement with the scaling relationship predicted by
DLVO theory. In analogy to the CFC, the ratio of divalent (calcium)
to monovalent (sodium) ion concentration needed to induce
diffusion-limited surfactant adsorption is proportional to 2−6,
which is, as far as we are aware, the ﬁrst demonstration of the
Schulze–Hardy rule for competitive adsorption. In designing surfac-
tant replacement formulations, it would be impractical to use 1 M
saline in a treatment due to its osmotic effects on lung tissue;
however, 15–20 mM CaCl2 added to physiological saline has minimal
effects on the ﬂuid balance in a rat lung (H. W. Tauesch, unpublished
observations). Trivalent ions should be even more effective in
enhancing surfactant adsorption and should be tested.
8. Polymers — two distinct mechanisms of destabilizing colloids
and enhancing adsorption
If the analogy between colloid stability and surfactant adsorption
holds, it would not be surprising that other additives used to
ﬂocculate colloids [90,135,181–186] should also lead to enhanced
surfactant adsorption in the presence of albumin or serum proteins.
The ﬁrst suggestion of the analogy between colloid stability and
surfactant adsorption came from observations that adding non-ionic
hydrophilic polymers such as polyethylene glycol (PEG) and dextran
[9,38,41,85,95,187–190] or anionic polymers such as hyaluronic acid
[13,94] to clinical lung surfactants improved lung function in animals
with lung injuries. This improved lung function correlated with
enhanced surfactant adsorption to an albumin-covered air–water
interface in vitro, as well as the ﬂocculation of the LS aggregates in
suspension [13,42,82–84,95,97,191].
9. Polymer depletion forces
The unifying features of the polymers that reverse inhibition by
this mechanism are: (1) they do not speciﬁcally adsorb to surfactant
aggregates; (2) the polymers show no surface activity by themselves;
(3) the polymers are small and at much higher number density
compared to surfactant aggregates (nm vs microns); and (4) inacti-
vation reversal occurs for all surfactant and polymer mixtures tried
thus far. This suggests that a generic interaction, the so-called
“depletion interaction” (Fig. 15), leads to inhibition reversal, rather
than a speciﬁc interaction between particular surfactants and
polymers. A mixture of two different sizes of non-interacting “hard
spheres”maximizes its entropy by maximizing the volume accessible
per “sphere” [192–199]. Here, the small spheres are the polymers
with radius of gyration, Rg (typically nm), and the large spheres are
surfactant aggregates of radius a (typically microns, see Figs. 4, 6). The
small spheres can approach the large spheres or the interface no
closer than Rg (hatched regions in Fig. 15), which prevents this
“excluded volume” from being explored by the polymers. As a large
sphere moves toward another large sphere or the interface, the
volume excluded from the centers of the small spheres (hatched
regions in Fig. 15) overlap, which causes the volume accessible to the
small spheres to increase (small volume at the bottom right of Fig. 15)
[192–197]. This increases the entropy of the mixture (decreases the
free energy) by an amount proportional to the size of the excluded
volume overlap region, multiplied by the osmotic pressure of the
small spheres. This leads to an attractive force between the large
spheres and between the large spheres and the interface.
Fig. 15. Origin of depletion forces in a binary sphere mixture. (Top) The centers of the
small spheres are excluded from the hatched regions within one small sphere radius
(Rg) of the larger spheres (radius R) or the interface. (Bottom)When the larger spheres
move to the interface or toward each other, the hatched regions overlap, and the total
volume accessible to the small spheres increases by this amount times the number of
large spheres (total increase in volume in the bottom right-hand corner). The increase
in the volume accessible to the polymer increases the entropy of the system, resulting
in a net “depletion” force pushing the large spheres toward the interface or each other.
Figure adapted from [42].
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volume available to the polymer results in an attractive force bet-
ween the sphere and the interface is by considering the osmotic
pressure of the polymer solution. Each large sphere immersed in a
polymer solution experiences an osmotic pressure acting normal to
its surface. For an isolated particle, this pressure is distributed
homogeneously over the entire surface, so the net force in any
direction is averaged out to zero. However, when two large spheres
approach each other closer than the effective size of the polymer,
2Rg, the polymer can no longer ﬁt into the gap between the large
spheres or between a large sphere and the interface; the polymer
will be excluded from a portion of the volume of the gap. Hence, in
the gap between the large spheres, or between the large sphere and
the interface, the polymer concentration is reduced, resulting in a
lower osmotic pressure in the gap (for an ideal solution, the polymer
osmotic pressure is ϕpkBT, in which ϕp is the volume fraction of
polymer). Consequently, the pressure on the large sphere due to the
polymer osmotic pressure becomes unbalanced, leading to a force
that pushes the large spheres toward each other, or toward the
interface: the depletion attraction.
Moving a single surfactant aggregate of radius a into contact with
the interface decreases the mixture's free energy by 3aϕpkBT/Rg [193–195,197], which is twice that of the decrease in free energy when two
aggregates come together 3aϕpkBT/2Rg. If the interface deforms, an
even larger excluded volume overlap region results, with a larger
force pushing the large sphere towards the surface [194,195,197]. The
depletion potential energy, W(r), as a function of separation, r,
between the large sphere and the interface [197] is simply a product
of the volume of the overlap region and the osmotic pressure as a
function of separation,:
WðrÞ = −3ϕpkBT
a
Rg
1− r
2Rg
 !2
ð16Þ
for rb2Rg, and W(r)=0 for rN2Rg. The depletion potential is
independent of the chemistry of the large and small spheres, as long
as the polymer does not adsorb to surfactant or interface.
The depletion potential (Eq. (16)) is generally assumed to be
additive with the DLVO potential (Eq. (14)) when considering the
simultaneous effects of polymers and electrolytes on colloid stability
[196] or surfactant adsorption in the presence of albumin [79]:
Φ= 32πεεo
kBT
ez
 2
a tanh
2 ezψs
4kBT
 
expð−κrÞ− aAH
12r
−3ϕpkBT
a
Rg
1− r
2Rg
 !2
ð17Þ
for rb2Rg. The depletion potential is always negative (attractive) so
depletion attraction will always help enhance colloid ﬂocculation or
surfactant adsorption by decreasing Φmax in Eq. (13). The magnitude
of the change depends on the Debye length, the surfactant aggregate
size, the polymer molecular weight and the polymer volume fraction.
Albumin and the other serum proteins are of order 4–10 nm in
diameter, while the surfactant aggregates are of order microns; hence
the depletion attraction is signiﬁcantly greater for the surfactant
aggregates. The depletion attraction is purely entropic, and is
independent of the chemical composition of the surfactant, protein
and polymer as long as the polymer does not adsorb to the surfactant
or the interface, which explains why PEG, dextran, and hyaluronan are
all effective at enhancing Survanta, Curosurf and Infasurf adsorption
{Taeusch, 2005 232; Lu, 2009 #884}.
Fig. 16 shows that the depletion forces between surfactant
aggregates can push the aggregates together against the inter-
aggregate repulsive forces and thermal motion that stabilizes the
aggregates in suspension. Large ﬂocs are formed that can be readily
redispersed by stirring or shaking the sample vials. The depletion
attraction between two spherical surfaces is only half that between
the sphere and the interface (Eq. (16)) because of the smaller
excluded volume overlap {Kaplan, 1994 #603}. However, Fig. 16
shows that even this smaller depletion attraction induced by 5 wt.%
10 kDa PEG is sufﬁcient to ﬂocculate Infasurf, Curosurf and Survanta
and overcome any electrostatic repulsion between the anionic
surfactant particles. Aggregation of surfactant particles after PEG
addition was also observed by Yu et al. {Yu, 2004 #601} and was
ascribed to depletion attraction. Lu et al. {Lu, 2009 #884} showed that
Infasurf particles were ﬂocculated by PEG, hyaluronic acid (HA) and
dextran, consistent with the depletion attraction mechanism,
although Survanta, while ﬂocculated by PEG and dextran, was not
ﬂocculated signiﬁcantly by HA. These large ﬂocs of surfactant, while
slower to diffuse, carry a substantially larger volume of material to the
interface when they do arrive.
10. Optimizing polymer volume fraction and polymer molecular
weight
The effects of the depletion attraction are best seen by the scaling
of surfactant adsorption with the volume fraction of polymer at a
constant surfactant and electrolyte concentration [83]. Eqs. (13) and
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polymer concentration (for a ﬁxed electrolyte concentration), and
only a linear dependence on surfactant concentration.
Fig. 16a shows the surface pressure as a function of trough area for
increasing amounts of Survanta deposited on a clean saline subphase.The characteristic shape of the isotherms in Fig. 3a are translated
unchanged (note the shape of the collapse plateau and the shoulder at
∼40 mN/m) from low to high trough area for a given surface pressure
as the amount of Survanta added to the trough is increased from 8 μg
up to 800 μg [137]. This means that the total amount of surfactant at
the interface has increased, as the relationship between surface
pressure and area/molecule is ﬁxed for a given surfactant composi-
tion and temperature (See Table 1) [97]. Hence, increasing surfactant
adsorption to the interface is reﬂected in the isotherms as a
translation from low to high trough area at a given surface pressure.
Eventually, the interface is saturated (note the small offset between
300 μg to 800 μg) and further increases in surfactant concentration
have little effect.
Fig. 16b shows the effect of albumin on the isotherms is equivalent
to decreasing the Survanta concentration (see Fig. 16a). The red line in
Fig. 3b shows the compression isotherm of 2 mg/ml albumin with no
Survanta or PEG, which differs little from that of 800 mg Survanta on
the albumin subphase, which means that the effective surfactant
adsorption is reduced by a factor of 100 by the albumin-inducedΦmax.
A N100-fold reduction in adsorption at ﬁxed bulk concentration, CB,
corresponds to a Φmax of approximately +5 kBT for the albumin–
surfactant potential, similar to the energy barrier estimated between
Curosurf and serum proteins from Fig. 2.
Increasing the concentration of 10 kDa PEG in the subphase
(Fig. 16b), like increasing the electrolyte concentration (Figs. 13, 14),
increases the adsorption of surfactant to the interface. As in Fig. 16a,
the shapes of the isotherms are unchanged, just shifted to larger
trough areas with increasing polymer concentration, conﬁrming that
the albumin and polymer do not affect the surfactant monolayer
properties at the interface, just the total surfactant adsorption. This is
consistent with the polymer inducing a depletion attraction between
the interface and the surfactant aggregates and reducing Φmax.
To quantify the effect of polymer concentration on surfactant
adsorption, Fig. 17 shows an estimate of the relative rate of surfactant
adsorption as a function of PEG concentration. The ﬂuorescence
images (Fig. 7c) and X-ray data (Figs. 8–11) show that very little
surfactant adsorbs to an albumin-covered interface on a subphase
with 150 mM salt. Hence, we approximate the relative adsorption, RA,
as the difference between the sample surface pressure (Π) and the
surface pressure of the albumin (Πalb∼23 mN/m) only isotherm (red
curve in Fig. 16b), divided by the difference between the surface
pressure for the saturated isotherm (N1% PEG in Fig. 16b, Π-
sat∼66 mN/m) and Πalb : RA = Π−ΠalbΠsat−Πalb jAo . All surface pressures
were evaluated by averaging over the same trough area (Ao) denoted
by the shaded area in Fig. 16b. This region showed the maximum
variation in adsorption.
Fig. 17 shows that the relative adsorption increases by about a
factor of 50 as the PEG concentration is increased from 0 to 0.8 wt.%.
Higher concentrations of PEG lead to minimal increases in adsorption,
as the interface becomes saturated with surfactant. From Fig. 14,
without the polymer, 1000 mM NaCl is required to restore surfactant
adsorption; hence, 0.8 wt.% 10 kDa PEG provides as much decrease in
Φmax as an additional 850 mM of NaCl. From Eqs. (13) and (17), the
relative adsorption with albumin and PEG in the subphase comparedFig. 16. Surfactant particles ﬂocculate on addition of 5 wt.% 10 kDa PEG. Curosurf,
Infasurf and Survanta form large, 20–100 μm size loose ﬂocs due to the depletion
attraction (compare to Fig. 6) {Zasadzinski, 2005 #233}. The ﬂocs can be redispersed by
stirring. Hyaluronic acid and dextran also ﬂocculate surfactant aggregates {Lu, 2009
#884}, consistent with a depletion attraction overcoming the electrostatic repulsion
due to the anionic lipids present in most lung surfactants. The depletion attraction
between surfactant particles is only half that between the particles and the interface, so
proportionally more polymer is required to ﬂocculate the particles than necessary to
enhance adsorption to the interface {Kaplan, 1994 #603}.
Figure adapted from {Zasadzinski, 2005 #233}.
Fig. 18. The relative adsorption (RA) is the difference between the sample surface
pressure (Π) and the surface pressure of the albumin-only isotherm (ΠAlb, red curve in
Fig. 3b), divided by the difference between the surface pressure for the saturated
isotherm (N1% PEG in Fig. 17b) and ΠAlb, RA =
Π−ΠAlb
Πsaturated−ΠAlb jA0 . All surface pressures
were evaluated by averaging over the same trough area denoted by the shaded area in
Fig. 17b. The solid line is a ﬁt to the data showing the exponential dependence of RA on
the polymer concentration as predicted by Eqs. (15),(16), consistent with the depletion
attraction lowering the DLVO energy barrier to surfactant adsorption.
Figure adapted from [83].
Fig. 17. Fourth compression cycle isotherms of increasing concentrations of Survanta on
a clean buffer subphase (a) and 800 μg Survanta on subphases containing 2 mg/ml
albumin with increasing PEG concentrations (b). (a) △ 8 μg Survanta; ⌂ 30 μg
Survanta; ◊ 80 μg Survanta; ○ 300 μg Survanta; □ 800 μg Survanta; At a given surface
pressure, the isotherms are translated essentially unchanged from low trough area to
high trough area with increasing Survanta concentration (note the characteristic
shoulder at ∼40 mN/m and the collapse plateau at ∼65 mN/m). This shows that
Survanta adsorption increases with increasing concentration as predicted by Eq. (12).
The interface becomes saturated for concentrations greater than about 300 μg ; the
800 μg isotherm is not displaced signiﬁcantly to higher trough areas. (b)□ Survanta on
saline buffer subphase with no albumin; ○ Survanta–albumin; ◊ Survanta–albumin–
0.25 wt. % PEG; ⌂ Survanta–albumin–0.50 wt. % PEG; △ Survanta–albumin–1.2 wt. %
PEG. The red curve shows the surface pressure for the albumin subphase with no
Survanta or PEG. Comparing to (a) shows that albumin in the subphase produces the
same effect as decreasing the Survanta concentration from 800 μg to about 8 μg. Adding
increasing amounts of PEG to the subphase shifts the isotherms to higher trough areas,
the same effect as increasing the Survanta concentration in (a). The shaded area
denotes the trough area over which the surface pressure was averaged for each PEG
concentration to obtain the relative surfactant adsorption plotted in Fig. 18.
Figure adapted from [83].
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fraction, CPEG:
ln
JPEG
JDL
 
= lnðRAÞ = α + βϕp = α + β′CPEG; ð18Þ
in which β, β′ and α are (unknown) constants for a given Survanta
and albumin concentration. While there is some scatter in the data,
the relative adsorption does depend exponentially on the PEG
concentration consistent with Eq. (18). This shows the proper scaling
for the depletion potential and that adding PEG lowers the energy
barrier to adsorption.
However, for a subphase with no added salt, Fig. 18 shows that
1 wt.% PEG did not lead to any increase in the adsorption of surfactant
in the presence of albumin. This is because the maximum in the DLVO
potential (Eq. (17)) occurs when the separation between the charged
surfaces, r, is of order κ−1. For the subphase with no added NaCl, the0.2 mM NaHCO3 buffer gives a κ−1 of ∼20 nm. The maximum range
of the depletion attraction, 2Rg, however, is only ∼10 nm for 10 kDa
PEG [42,83,84,200]. Hence the range of the depletion attraction is not
sufﬁcient, regardless of the polymer concentration, to affectΦmax, and
PEG has no effect on adsorption (Fig. 18), as observed. For 150 mM
salt, κ−1∼1 nm, 2RgNNκ−1 and the range and magnitude of the de-
pletion attraction is sufﬁcient to lower Φmax enough to restore
diffusion-limited adsorption [83,84].
These results show that there is a minimum Rg (Eq. (16)) neces-
sary to induce the depletion attraction, and hence a minimum
molecular weight necessary to generate a depletion attraction [192–
195,197]. If the molecular weight, and hence the diameter of the
polymer, is too small, the range of the depletion attraction may not
overlap the range of the repulsive interactions. For molecular weights
above this minimum, Eq. (16) can help predict the optimal
concentration for a given molecular weight. The osmotic pressure of
the polymer–surfactant solution, which should be minimized to
prevent inﬁltration of liquid into the lung, is proportional to Np/V; so
high molecular weight polymers should have a distinct advantage in
treatments of ARDS and other lung injuries. Saline is a good solvent for
PEG and other hydrophilic polymers and several authors have shown
that Rg∝MV0.55, in which MW is the polymer molecular weight
[200,201]. The range of the depletion attraction is proportional to Rg
and hence should increase as MW0.55. From Eq. (16), ϕp∼NpR
3
g
.
V
in
which Np is the number of polymer molecules in a volume V. For a
ﬁxed polymer weight fraction of ρ, Np = ρV
	
MW , hence the depletion
potential for PEG should scale only weakly with molecular weight as
Wmax∝ϕp∝MW0.1, below the polymer entanglement concentration
(which also depends on molecular weight).
Fig. 19 shows three distinct responses as a function of PEG
molecular weight for Survanta adsorption to an albumin-covered
interface on subphase containing physiological saline. Region I
corresponds to minimal reversal of surfactant adsorption inhibition,
Region II corresponds to complete reversal of adsorption inhibition
and Region III corresponds to partial reversal of adsorption inhibition.
In Region I, for the lowest molecular weight PEG's, the range of the
depletion attraction is small compared to the range of the repulsive
interactions as in Fig. 18; Φmax in Eq. (13) is not decreased and the
polymer has little effect on surfactant adsorption. Some combination
of the albumin ﬁlm thickness and the Debye length likely deﬁnes the
Fig. 19. Fourth cycle compression isotherms of 800 μg lipid dispersion on a buffered
subphase (0.2 mM NaHCO3 and pH=7) containing 2 mg/mL albumin, 10 mg/mL
10 kDa PEG and varying NaCl concentrations. Filled symbols denote subphases
containing albumin and NaCl while open symbols denote subphases containing
albumin, NaCl and PEG. ■ 0 mM NaCl–albumin subphase; □ 0 mM NaCl–albumin–PEG
subphase; ● 150 mM NaCl–albumin–subphase; ○ 150 mM NaCl–albumin–PEG
subphase. Adding PEG restores the characteristic shoulder and collapse plateau of the
Survanta with 150 mM NaCl in the subphase, but the same amount of PEG added to a
0 mM NaCl subphase does not alter the albumin-like isotherm. The range of the
depletion attraction induced by PEG is twice the radius of gyration of the polymer,
about 9 nm for 10 kDa PEG, which is less than the Debye length of 13 nm for the 0 mM
NaCl subphase. For 150 mM NaCl, the Debye length is 1 nm, so the PEG induced
depletion attraction has sufﬁcient range to lower the repulsive potential.
Figure adapted from [79].
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minimum-range of a depletion attraction necessary to enhance
surfactant adsorption. The range of the depletion attraction induced
by 1.45 kDa PEG (2Rg∼3.0 nm) is less than the axial dimension of the
albumin molecule, so we expect minimal effects on surfactant
adsorption as observed (Fig. 19). The range of the 3.35 kDa PEG
depletion attraction (2Rg∼4.8 nm) is about the same as the albumin
dimensions, but the depletion potential is still apparently much
smaller than the ∼5 kBT repulsive energy barrier estimated earlier
[83], so there is only a small effect on adsorption.
For the intermediate molecular weight range in Region II, the
depletion interaction is sufﬁciently long-ranged that it overlaps the
repulsive interactions and leads to greatly enhanced surfactant
adsorption. From Eq. (18), since Wmax∝ϕp∝MW0.1, ln(RA) should
also be proportional to MW0.1. In Fig. 19, for 1 wt.% PEG over the
molecular weight range of 6–35 kDa (Region II), the dashed line in
Fig. 19, ln (RA)∝MW0.1, ﬁts the data quite well. Though there is more
scatter in the data, the scaling law also holds reasonably well for
0.5 wt.% PEG over this range of molecular weights.
However, the scaling does not continue for higher molecular
weights, in fact, surfactant adsorption decreases for the higher
molecular weight PEG at both 0.5 and 1.0 wt.% indicating a smaller
depletion attraction (Region III). For these PEGmolecular weights, the
ratio of polymer solution viscosity to the solvent (saline) viscosity, η/
ηsol, at wt.% polymers exceeds the overlap criterion, η/ηsolN2. As the
polymer solution approaches the overlap concentration and crosses
into the semi-dilute regime, the polymer is no longer isolated random
coils with characteristic length scale Rg but is instead an entangled
polymer mesh with characteristic length scale ξ. Above overlap, the
simple hard spheremodel (Eq. (16)) [192] for the depletion attraction
must be modiﬁed [202–204]. For a dilute colloidal systemwith a large
aspect ratio between the colloid (a∼500 nm) and polymer
(Rg∼20 nm), the modiﬁed theory predicts that the magnitude of the
depletion attraction will plateau at roughly the polymer overlap
concentration. 200 kDa PEG reaches its overlap at signiﬁcantly lower
concentrations (∼0.5 wt.%) than 10 kDa PEG (∼4.0 wt.%), which
explains why the PEG 200 kDa depletion attraction is lower inmagnitude and yields lower RA values for PEG molecular weights in
Region III. The plateau of the depletion attraction at roughly the
overlap concentration gives an upper limit for the effectiveness of a
polymer of a given molecular weight; any additional polymer above
the overlap concentration no longer increases surfactant adsorption.
However, further increasing the polymer concentration greatly
increases the solution viscosity; as Deff in Eq. (12) is inversely
proportional to the solution viscosity, too much polymer over the
overlap concentration will cause the net rate of adsorption to
decrease.
Yu et. al. also showed that increasing PEGmolecular weight (from
3.35–35 kDa) enhanced the rate of bovine lipid extract surfactant
absorption to a clean interface [95], while higher molecular weight
PEG (300 kDa) did not enhance adsorption. Surface force apparatus
(SFA) measurements between mica-supported lipid bilayers in
10 wt.% 1 kDa PEG yielded a force–distance proﬁle similar to pure
water, indicating at this low molecular weight, the PEG does not
generate a depletion attraction [205,206] Kuhl et. al. also showed a
concentration dependant increase in the adhesion force between
lipid bilayers in the SFA for solutions containing 8 or 10 kDa PEG,
which quantitatively agrees with that expected for a depletion
attraction between the bilayers [205,206].
Though the compression and expansion cycles on the Langmuir
trough are slow (8 min/cycle) compared to physiological rates (3 s/
cycle), previouswork performed on the pulsating bubble surfactometer
shows that PEG, dextran and hyaluronic acid enhance surfactant
adsorption at physiological rates [38,41,85,87,94,95,163,188,190,191].
An additional factor to consider in future treatments is that the osmotic
pressure of the polymer–surfactant solution must be minimized to
prevent inﬁltration of liquid into the lungs during any potential ARDS
treatment [207]. Hence, the lowest concentration of the highest
molecular weight polymer that provides the necessary inhibition
reversal should be used; the optimal PEG molecular weight for
surfactant inhibition reversal is therefore likely to be around 35 kDa;
which provides the greatest depletion attraction/surfactant adsorption
with the smallest osmotic pressure [84,190]. A caveat to this optimal
molecularweight is that it dependson theconcentrationof thepolymer;
the use of higher polymer concentrations results in overlap and a
corresponding plateau in enhanced surfactant adsorption. A further
advantage of using 35 kDa PEG compared to smaller molecular weights
is the increased range of the depletion attraction (2Rg). Other serum
proteins such as ﬁbrinogen have also been shown to competitively
adsorb with lung surfactant lipids; ﬁbrinogen is larger than albumin
with dimensions of 5×5×46 nm [208]. While the exact orientation of
ﬁbrinogen at the air–liquid interface is unknown, the higher molecular
weight PEG can likely generate a depletion attraction with sufﬁcient
range and magnitude to enhance surfactant adsorption.
While molecular weights of 6–35 kDa are optimal for PEG, other
polymers may exhibit optimum molecular weights, which are larger
or smaller depending on composition, overlap concentration and
charge. For example, hyaluronan (HA), a natural polysaccharide that
is secreted by alveolar epithelial cells, of molecular weight 100–
1240 kDa has been shown to reverse surfactant inhibition in vitro
[13,87,94,191] at much lower concentrations than PEG. Hyaluronan is,
like albumin and LS, anionic, which makes for an even large effective
excluded volume (Fig. 15) and large depletion potential. The
electrostatic repulsion between the LS aggregates and anionic
polymer increases the effective radius of both the surfactant
aggregates and the polymers by roughly the Debye length, [196].
HA occurs in the lung epithelial ﬂuid at concentrations of 4000 μg/L
with a molecular weight of 220 kDa, in contrast to the 2000 kDa HA in
cartilage and 7000 kDa HA in synovial ﬂuid [209], suggesting an
optimized HA molecular weight in the lung. During lung injury and
disease, HA can be broken down by enzymatic action to produce
smaller molecular weight fragments (1.6 kDa–10 kDa) [209]. How-
ever, similar to Region I of Fig. 19, these fragments may generate
Fig. 20. Relative adsorption (RA, See Fig. 18) of 800 μg Survanta on subphases
containing 2 mg/mL albumin at varying PEG molecular weights and concentrations.
○ 1 wt.% PEG; □ 0.5 wt.% PEG; △ 0 wt.% PEG which has been plotted for comparison
purposes. Region I (PEG 1.45–3.35 kDa) corresponds to minimal reversal of surfactant
adsorption inhibition, Region II (PEG 6–35 kDa) corresponds to complete reversal of
adsorption inhibition and Region III (PEG 100–200 kDa) corresponds to partial reversal
of adsorption inhibition. The dashed line, where RA depends on theMW 0.1, is a good ﬁt
to the PEG 1 wt.% data in Region II, consistent with the depletion attraction lowering the
energy barrier to surfactant adsorption.
Figure adapted from [84].
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adsorption, especially in the presence of serum proteins.
GIXD and X-ray reﬂectivity conﬁrm the basic assumption of the
depletion attraction model at the molecular scale. Fig. 20 shows
the Bragg peaks (Fig. 20a) and rods (Fig. 20b) from GIXD scans of
600 μg Survanta spread on a subphase with 2 mg/mL albumin and
5 wt.% PEG. Prior to spreading the Survanta, the surface pressure
was ∼18 mN/m, indicating albumin had adsorbed to the interface.Fig. 21. Bragg peaks and rods from GIXD of 600 μg Survanta spread onto a subphase conta
changes from distorted hexagonal to hexagonal at a lower surface pressure than Survanta on
pressure than Survanta on the control subphase. PEG in the subphase compacts the Survanta
subphase. It may be that PEG induces a lateral “depletion attraction” within the ﬁlm, as well
overall phase progression, lattice spacings and tilt were little changed from Survanta on a
depletion attraction that enhances surfactant adsorption.
Figure adapted from [97].However, after spreading Survanta, the characteristic Survanta
diffraction peaks were observed everywhere on the interface. At
20 mN/m, q10=1.48 Å−1 and q11=1.49 Å−1; the Bragg rods have a
local maximum at qz=0.09 Å−1. Compared to Survanta at 20 mN/m,
the PEG in the subphase appears to condense the Survanta lattice
somewhat and slightly reduce the tilt (Table 1). By 30 mN/m, the
lattice has further condensed with q10=1.50 Å−1 and qz=0 Å−1,
indicating that the molecules are hexagonally packed and normal to
the interface. At 40 mN/m, the main peaks remains at qxy=1.50 Å−1.
The Bragg rods again show no local maximum above the horizon
(qz=0 Å−1) at 40 mN/m indicating that the molecules are normal to
the interface.
Fig. 21 shows the electron density proﬁles for Survanta spread on a
subphase containing both 2 mg/mL albumin and 5 wt.% PEG. The
albumin–PEG subphase has an electron density proﬁle similar to
albumin (Fig. 11), with a maximum electron density of ρ/ρsub=1.18
at Z=15 Å. However, the albumin–PEG subphase proﬁle decreases
more quickly than albumin and reaches a minimum value of 0.95,
suggesting a PEG depletion layer. For Survanta on an albumin–PEG
subphase at 20 mN/m, the electron density proﬁle is qualitatively
similar to albumin for Zb50A, indicating that the interfacial ﬁlm
within the beam footprint is dominated by albumin. However, GIXD
for the same ﬁlm at 20 mN/m (Fig. 20) shows diffraction peaks,
indicating that some ordered Survanta coexists at the interface. The
Survanta–albumin–PEG 20 mN/m electron density proﬁle decreases
less quickly than that for the albumin–PEG subphase; for ZN50 A, it
overlaps with the Survanta electron density proﬁle. For Survanta–
albumin–PEG at 30 mN/m and 40 mN/m, the electron density proﬁles
are more similar to Survanta on the control subphase, indicating that
at higher surface pressures, Survanta has displaced albumin from the
interface. However, ρ/ρsubN1 at larger Z, which may be due to
albumin remaining near the interface. However, the PEG depletion
layer might mask the magnitude of this effect. Overall, when PEG and
albumin are in the subphase, XR and GIXD show that the Survanta
displaces albumin from the subphase as the surface pressure increasesining 2 mg/mL albumin and 5 wt.% PEG. (a) Bragg Peaks at 20–40 mN/m. The packing
the control subphase. (b) Bragg rods at 20–40 mN/m. Zero tilt occurs at a lower surface
lattice and eliminates the molecular tilt at a lower surface pressure compared to control
as inducing the depletion attraction that forces Survanta to the interface. However, the
saline subphase (Fig. 8), showing that the primary effect of adding PEG is to induce a
821J.A. Zasadzinski et al. / Biochimica et Biophysica Acta 1798 (2010) 801–828and that PEG has a depletion layer at the interface, consistent with the
depletion attraction model.
11. Cationic polyelectrolytes
The third common method of ﬂocculating charged colloids, which
has a long history in wastewater treatment, mineral processing,
ceramics manufacture and papermaking, relies on adding oppositely
charged polyelectrolytes to the colloidal suspension [181–186].
Cationic polyelectrolytes, such as chitosan, are particularly useful, as
they are oppositely charged to the negatively charged surfaces
common to natural systems. In analogy to its coagulating effects on
colloid stability, chitosan improves the adsorption of lung surfactant
to the air–water interface in the presence of albumin. In contrast to
the ∼10 mg/ml of 10 kDa PEG necessary to enhance adsorption by the
depletion attraction, as little as 1 µg/mL if chitosan is able to provide
the same level of enhancement [81,96,136] under otherwise identical
conditions. These chitosan concentrations are much too low to induce
a depletion attraction, which is proportional to the polymer volume
fraction (See Figs. 15–21). However, in the same way that divalent
calcium requires signiﬁcantly lower concentrations to enhance
adsorption than monovalent sodium, increasing the valence to
+100 for high molecular weight chitosan should lead to very low
concentrations by the Schulze–Hardy rule (Eq. (15)). However, unlike
calcium or PEG, increasing the chitosan concentration above optimal
causes less surfactant to adsorb and inactivation re-occurs. Only a
narrow window of chitosan concentration completely reverses
inhibition.
Chitosan, like many other cationic polyelectrolytes, ﬂocculates
negatively charged colloids at low concentrations, then redisperses
and stabilizes the colloid at higher concentrations [181–186]. The
mechanism of action for both colloid aggregation and surfactant
adsorption is consistent with an initial charge neutralization of the
anionic surfaces by the cationic polymer [181–186], which causes an
elimination of the double-layer repulsion. However, as is often the
case for polyelectrolytes, higher polymer concentrations lead to over-
compensation of the surface charge, which re-establishes theFig. 22. The electron density proﬁles, normalized by the subphase electron density,
determined by X-ray reﬂectivity for 600 μg Survanta spread on a subphase containing
2 mg/mL albumin and 5 wt.% PEG. No Survanta was present for the albumin–PEG
subphase data. The albumin–PEG subphase has an electron density proﬁle similar to
albumin (Fig. 11), with a maximum electron density of ρ/ρsub=1.18 at Z=15 Å.
However, the albumin–PEG subphase proﬁle decreases more quickly than albumin and
reaches a minimum value of 0.95, suggesting a PEG depletion layer. At 20 mN/m, the
electron density proﬁle is similar to albumin, while for 30 and 40 mN/m; the electron
density is similar to Survanta, indicating Survanta has displaced the albumin. The
electron density proﬁle of 200 μg Survanta on the control subphase at 40 mN/m is
shown for comparison. The measured electron density is consistent with a PEG
“depletion layer” at the interface, which validates one of the major requirements of the
depletion attraction.
Figure adapted from [97].electrostatic energy barrier [181–186], leading to a decrease in
surfactant adsorption. The same physical mechanism is observed in
ﬂocculation and re-stabilization of anionic colloids by chitosan [181–
183,185] and in alternate layer deposition of anionic and cationic
polyelectrolytes on charged colloids [184,186].
Fig. 22a and b shows the effect of varying chitosan concentrations
on Survanta (800 μg) deposited onto a subphase containing 2 mg/mL
albumin. A chitosan concentration of only 0.1 µg/mL (Fig. 22a, penta-
gons) reached a maximum surface pressure of 45 mN/m. Increasing
the chitosan concentration to 0.5 µg/mL (Fig. 2a, up-triangles)
restored the characteristic shoulder and collapse plateau at a lower
trough area than Survanta on a clean interface (Fig. 22a, squares),
indicating less total surfactant adsorption. For chitosan concentrations
of 1–5 µg/mL (Fig. 22a, left-triangles, right-triangles), the character-
istic shoulder and collapse plateau occur at similar trough areas as on
an albumin-free interface, indicating an equivalent amount of total
surfactant adsorption. In fact, more Survanta adsorbs for the optimal
chitosan concentration of 1 µg/mL than on a clean interface — the
isotherm is shifted to larger trough areas at all surface pressures. The
minimum surface tension of the ﬁlms also increases with increasing
chitosan concentrations. Kang et al. [136] also observed higher
minimum surface tensions and changes in cyclic isotherms at high
chitosan concentrations, just as in Fig. 12 for higher salt concentra-
tions. Note that the surface pressures of the characteristic shoulder
and the collapse pressure of the Survanta does not change with
chitosan concentration, once adsorption has been restored.
However, increasing the chitosan concentration above this
optimum value yields a gradual decrease in surfactant adsorption
(Fig. 22b). Increasing chitosan concentrations shift the characteristic
shoulder and collapse plateau to a lower trough area without altering
the surface pressures at which they occur. While surfactant
adsorption at 0.5 mg/mL (Fig. 22b, up-triangles) is decreased from
the optimum chitosan concentration (5 µg/mL, up-triangles), the
isotherm is still representative of an interface with Survanta
compared to the isotherm of albumin alone.
Chitosan by itself is not surface-active over the range of
concentrations used and does not affect the surface pressure of
albumin. Albumin reaches amaximum surface pressure of ∼31 mN/m
upon compression and a minimum surface pressure of ∼13 mN/m
upon expansion indicating that its adsorption and surface activity are
unchanged by chitosan [80]. Saline buffer containing 0.0005–0.5
chitosan and 2 mg/mL albumin are optically clear, putting an upper
limit on the aggregation in the bulk. Other reports show that chitosan
does not signiﬁcantly increase the turbidity of an albumin solution at
salt concentrations used in this work, conﬁrming that chitosan does
not cause large scale aggregation of the albumin in solution [210].
Adsorption of cationic polyelectrolytes to anionic colloids initially
leads to a decrease of the overall net particle charge with a resulting
decrease in the particle surface potential, ψs, in Eq. (14), thereby
reducing Φmax. At a certain polymer concentration, the negative
charge in the double-layer is neutralized by the polycation; ψs and
Φmax in Eq. (14) go to zero, resulting in rapid aggregation [186].
However, with further increases in the polyelectrolyte concentration,
the adsorption continues beyond net neutrality and leads to a charge
reversal of the colloid, creating a positive surface charge, +ψs , and a
new repulsive potential between the two positive colloidal surfaces,
Φpos, leading to a re-stabilized colloidal dispersion [181–186].
The effects of polyelectrolytes on charge-stabilized colloids
parallel those of the cationic chitosan on the adsorption of the anionic
lung surfactant in the presence of anionic albumin: ﬁrst an increase in
adsorption at low chitosan concentrations, followed by a decrease in
adsorption for higher chitosan concentrations (Fig. 22). Polyelec-
trolytes, in general, adsorb to surfaces of opposite charge because the
entropy increase caused by the release of the polymer and surface
counterions to the solution; the positively charged amide groups on
the chitosan can form ion pairs with oppositely charged ions on the
Fig. 23. Fourth cycle compression isotherms of 800 μg Survanta on a saline buffered
subphase containing albumin (2 mg/mL when present) and the stated chitosan
concentrations. (a) □ Survanta; ○ Survanta–albumin; ▹ Survanta–albumin with0.005 mg/mL chitosan, ◃ Survanta–albumin with 0.001 mg/mL chitosan; △ Sur-
vanta–albumin with 0.0005 mg/mL chitosan;⌂ Survanta–albumin with 0.0001 mg/mL
chitosan. In this concentration regime, increasing chitosan concentration yields
increasing surfactant adsorption. Charge neutralization of the Survanta and albumin
is reached between 0.0005–0.005 mg/mL chitosan [80]. Note that for .001 mg/ml
chitosan, more Survanta adsorbs (isotherm shifted to larger trough areas) than the
control Survanta on a clean subphase. (b) □ Survanta; ○ Survanta–albumin; △
Survanta–albumin–chitosan 0.5 mg/mL,∇ Survanta–albumin–chitosan 0.1 mg/mL; ◃
Survanta–albumin–chitosan 0.01 mg/mL; ▹ Survanta–albumin–chitosan 0.005 mg/mL. For chitosan concentrations greater than that necessary for charge neutralization
(Fig. 24), surfactant adsorption decreased. The shaded area denotes the trough area
over which the surface pressure was averaged for each chitosan concentration to obtain
the surfactant relative adsorption plotted in Fig. 24.
Figure adapted from [80].
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double layer, ψs, is neutralized and the surface potential is reduced to
zero (Eq. (14)). However, this net neutralization cannot explain
charge reversal; it is necessary to consider the details of the charge
distribution of the surfaces and the polymers.
In comparison to a solution of molecular ions like sodium or
calcium, the positive charges on chitosan and other polyelectrolytes
have a ﬁxed separation and often cannot adjust their spacing to
neutralize a stoichiometric number of charges ﬁxed on a surface. X-
ray crystallography shows that the amide groups in chitin are about
1.5 nm apart, so the spacings between charges in nearly fully
deacyltated chitosan should be similar [181,182]. It is unlikely that
the normal separations between negative charges in Survanta or
albumin are compatible with the separation between amide groups
on the chitosan. In lung surfactant monolayers, the area permolecule
for the liquid condensed phase of phosphatidylglycerol (the most
common anionic lipid in Survanta) is about .45 nm2 [20], so a rough
estimate of the minimum separation between negative charges is
0.7 nm. The distances between negative charges in albumin are also
likely not compatible with the spacing between charges on chitosan.
Hence, a chitosan molecule with n+ positive charges would not be
capable of forming ion pairs with an equivalent number, n−, of
surface charges, as would be the case for n+ individual sodium ions,
for example. Hence, while n+ positive charges on chitosan adsorbed
to the surfactant or albumin can neutralize the average “smeared”
net n− negative charges in the double layer, resulting in a zero net
potential in Eq. (14), the surface itself remains heterogeneous with
patches of positive and negative charges [183–186]. Such a
heterogeneous surface can lead to a short range “dipolar attraction”
between the interfacial albumin and the surfactant bilayer aggre-
gates, leading to a net attractive interaction between the surfactant
and the interface. The can lead to enhanced adsorption even relative
to a clean surface. In Fig. 22a, for chitosan concentration of 1 µg/mL,
the amount of Survanta adsorbed to the interface in the presence
of albumin is even greater than the control adsorption to a clean
interface.
Additional chitosan can continue to adsorb as the polycation sees
both attractive negative and repulsive positive charges on the surface
while the net potential is low. The added chitosan can form ion pairs
with the remaining negative charges on the surfactant or albumin
surfaces. This over-compensation of charge is common; for example,
certain polycations adsorb on net positively charged TiO2 surfaces,
where both positive and negative point charges coexist [186]. The
result is a charge reversal as more positive ions are present in the
vicinity of the surfaces than negative ions; chitosan continues to
adsorb until the surfaces are sufﬁciently positively charged that the
positively charged polymer is repelled from the surface by a now
positive surface potential (Eq. (14)) [184–186]. Kang et al. [136] have
shown that the surface potential of surfactant aggregates changes
from negative to positivewith increasing chitosan concentrations. The
net positively charged albumin and surfactant particles again have a
repulsive interaction with a new value of Φpos, leading to a decreased
rate of surfactant adsorption to the interface. A contributing effect to
the reduction of adsorption at higher chitosan concentrations may be
that chitosan adsorbed to the Survanta aggregates hinders the
conversion of the Survanta bilayers to monolayers. Chitosan adsorbed
to giant unilamellar vesicles stabilized the spherical bilayer structure
against changes in pH or osmotic pressure [211] that completely
disrupted unprotected vesicles.
True equilibrium between the polycation and the anionic colloid is
almost never obtained; polyelectrolyte adsorption is yet another case
of kinetically hindered equilibrium. While each electrostatic ion pair
between the polymer and the surface is weak, the large number
possible between the polyelectrolyte (chitosan has ∼500 cationic
amine sites/molecule) and the negative chargesmakes the adsorption
effectively irreversible [184–186]. Once bound, the polycation cannotreadily adjust its position on the surface to neutralize the equivalent
number of negative charges, especially if the charge distribution on
the polymer does not match that on the surface. If the adjacent
solution is diluted, the pH changed, etc., the polyelectrolyte does not
necessarily desorb; there is a pronounced adsorption hysteresis that is
typical for kinetically hindered equilibrium. This irreversibility of
adsorption, combined with charge reversal makes possible the
preparation of polyelectrolyte multilayers of anionic and cationic
polymers on a variety of substrates including multilamellar liposomes
[184–186].
Fig. 23 shows a quantitative demonstration of the effects of this
chitosan-induced charge neutralization followed by charge over-
compensation on the adsorption of lung surfactant to an albumin-
covered interface. The relative adsorption, RA, increases about 20
times as the chitosan concentration is increased from 0 to 5 µg/mL;
subsequent increases in chitosan concentration result in roughly a
ﬁve-fold decrease in RA from the maximum. The optimal concen-
tration range to enhance surfactant adsorption by chitosan (RA∼1) is
Fig. 24. Relative adsorption (RA) of 800 μg Survanta on subphases containing 2 mg/mL
albumin at varying chitosan concentrations. □ Survanta–albumin–chitosan; ○ Sur-
vanta–albumin, which as been plotted at a chitosan concentration of 7×10−5 mg/mL
for comparison purposes. All surface pressures were evaluated by averaging over the
same trough area, A0, denoted by the shaded area in Fig. 23. The relative adsorption
increases with chitosan concentration to an optimum value of RA ∼1 at .001–0.005 mg/
mL chitosan and then decreases with subsequent increases in chitosan concentration.
The dashed box indicates the calculated chitosan concentration range where n+/n−=1
(0.0005–0.005 mg/mL) [80]. The optimum RA occurs in this chitosan concentration
range consistent with a chitosan neutralizing the negative surface charge on the
albumin and surfactant, thereby eliminating the electrostatic energy barrier to
surfactant adsorption. Higher chitosan concentrations above n+/n−=1 lead to charge
reversal as excess chitosan adsorbs to the albumin and surfactant, leading to a net
positive charge in the double layer and a restored energy barrier to adsorption
(Eq. (14)).
Figure adapted from [80].
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1 µg/mL chitosan in the presence of albumin than on a clean
interface. Estimates show that this concentration range of chitosan is
approximately that needed to neutralize the surface charge on the
albumin at the interface and the surfactant. This range is shown as
the dashed box in Fig. 23, which should provide the greatest decrease
in both ψs and Φmax; the concentration range within the dashed box
corresponds to the highest RA. This result is consistent with charge
neutralization leading to enhanced surfactant adsorption. The higher
adsorption at 1 µg/mL chitosan is consistent with the formation of a
heterogeneous surface with patches of positive and negative charges
on the surfactant and albumin, which provide a dipolar attraction at
close range. At higher chitosan concentrations, the surfactant and
albumin at the interface are net positively charged, resulting in a
partially restored +ψs and Φpos and the albumin inhibition is only
partially reversed. It should be noted that in our system, chitosan
enhances surfactant adsorption (RAN0.2) relative to albumin even at
chitosan concentrations two orders of magnitude higher than charge
neutralization, yielding a broad window of enhanced surfactant
adsorption (Fig. 24). A possible explanation for this behavior is that,
from studies of alternate layer polyelectrolyte adsorption on
surfaces, chitosan and other polyelectrolytes eventually saturate
the surface and do not continuously increase the surface charge and
surface potentialwith increasing bulk chitosan concentration [184,186].
Once the surfaces are saturated, the excess chitosan and counterions in
solution reduce the Debye length, so that the electrostatic interactions
due to the cationic polymers on the surfaces are shielded by the higher
electrolyte concentration and resulting smaller Debye length (Eq. (14)).
This likely slows the decrease in surfactant adsorption with increasing
chitosan concentration, just as is observed for higher electrolyte concen-
trations in Figs. 13, 14. This optimal window of enhanced adsorption
with the cation/anion charge ratio is almost identical to that reported
for the stability ratio for chitosan induced ﬂocculation of anionic
colloidal particles [181–183].12. Conclusions
A necessary [13,42,79–84,97], but not sufﬁcient condi-
tion [58,60,61,212] for surfactant activity is to have sufﬁcient LS
adsorbed to the interface from the type II cells that line the alveoli, or
from an exogenous surfactant suspension. The competitive adsorption
of serum proteins to the air–water interface can inhibit the adsorption
of lung surfactant, leading to poor surfactant performance. Many
serum proteins are surface-active and water-soluble and can quickly
diffuse to an air–water interface. Albumin (as well as any other
surface-active material) adsorbed at the alveolar air–water interface
induces an energy barrier that inhibits surfactant transport to the
interface, thereby slowing surfactant adsorption. The physical pro-
cesses governing surfactant transport to an interface are identical to
those that determine colloid stability; the energy barrier that limits
surfactant adsorption in the presence of serum proteins is directly
analogous to those that lead to colloid stability against aggregation.
The energy barrier to surfactant adsorption is primarily electrostatic; a
double-layer repulsion arises due to the negative lipids in lung
surfactant and the net negative charge on albumin (and other serum
proteins) at the interface. Classical methods of manipulating the
double-layer repulsion in colloids using electrolytes have similar,
predictable effects on surfactant adsorption. Decreasing the electrolyte
concentration below physiological levels increases the Debye length
and the magnitude and range of the double-layer repulsion, which
eliminates surfactant adsorption even in the presence of the polymer
induced depletion attraction. Conversely, increasing the bulk electro-
lyte concentration well above physiological levels restores surfactant
adsorption in the presence of albumin without the need for added
polymer. Divalent calcium enhances surfactant adsorption at concen-
trations 2−6 lower that monovalent sodium, in good agreement with
the classical Schulze–Hardy rule for the critical ﬂocculation concen-
tration for colloids. Hydrophilic, non-adsorbing polymers such as PEG,
dextran and hyaluronic acid induce a depletion attraction between the
LS aggregates and the interface that can lower the repulsive potential
and enhance adsorption. Cationic polyelectrolytes such as chitosan, in
analogy to their effects on colloid stability, improve the adsorption of
LS at extremely low concentrations of 1 µg/mL compared to ∼10 mg/
ml for 10 kDa PEG or ∼1 mg/ml for 1240 kDa hyaluronic acid under
otherwise identical conditions. However, unlike PEG or HA, increasing
the chitosan concentration above optimal causes surfactant inhibition
to re-occur. Only an optimal range of chitosan concentration reverses
inhibition, which is identical to that observed in ﬂocculation of
colloidal particles by chitosan and other cationic polyelectrolytes. The
mechanism of action for both colloid aggregation and surfactant
adsorption is consistent with an initial charge neutralization of the
anionic surfaces by the cationic polymer, which causes an elimination
of the double-layer repulsion. However, as is often the case for
polyelectrolytes, higher polymer concentrations lead to over-com-
pensation of the surface charge, which re-establishes the electrostatic
energy barrier, leading to a decrease in surfactant adsorption. These
results conﬁrm the fundamental importance of electrostatics in
determining the competitive adsorption of surfactant as well as the
analogy between surfactant adsorption and colloid stability.
In short, every additive known to de-stabilize a charged colloidal
suspension also enhances the competitive adsorption of LS to an
albumin-covered interface: hydrophilic polymers that induce a
depletion attraction [42], increased concentrations of molecular
electrolytes that reduce the Debye length and screen the double-
layer repulsion [79], and polycations that ﬁrst neutralize the double-
layer repulsion, then over compensate and re-stabilize the colloidal
dispersion [80]. The simple analogy between colloid stability and
competitive adsorption appears to be both qualitatively predictive
and quantitatively accurate and the same scaling laws that determine
the optimal concentrations for coagulating colloids appear to work
well for enhancing surfactant adsorption.
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albumin, PEG, calcium, and chitosan can have speciﬁc effects that
depend on surfactant composition and phase behavior. Comparing
ﬂuorescence images, GIXD, XR, and isotherms of Survanta on clean or
albumin-covered interfaces with added chitosan [80], higher than
physiological electrolyte concentrations [79], or with added PEG
[82,83,97] in the subphase shows that the morphology and molecular
organization of Survanta does not change, conﬁrming that all of these
treatments leave the surfactant ﬁlm essentially intact; only the
transport to the interface is enhanced. For all methods of enhancing
adsorption [58,79–84,97], the adsorption processes are similar:
(1) Albumin (or serum proteins or lysolipids) initially occupies the
entire interface; the smaller size of albumin and its molecular
solubility compared to LS aggregates promotes faster diffusion
to the interface
(2) LS breaks through the albumin ﬁlm, depending on the
subphase conditions and the presence of additives that also
promote coagulation of colloidal particles, during cycling and
coexists with albumin in discrete domains on the interface
(3) If sufﬁcient LS adsorbs such that the surface pressure is raised
to N45 mN/m during compression, the albumin is completely
expelled from the interface.
(4) LS prevents subsequent albumin re-adsorption to the interface;
the ﬂuorescence images show behavior typical of Survanta on
a clean subphase including cracks and folds at the collapse
plateau.
Albumin expulsion from the interface (step 3) occurs completely
only over an optimal chitosan concentration range (1–5 µg/mL);
higher and lower chitosan concentrations do not fully expel the
albumin from the interface. Similarly, at lower than optimal
concentrations, electrolyte and PEG also show LS break-through but
not complete expulsion of the albumin. LS entirely expels the albumin
at higher PEG or electrolyte concentrations [58,79–84,97]. It appears
that the surface pressure must reach levels much higher than the
equilibrium surface pressure of albumin (∼20 mN/m) to completely
remove albumin from the interface [58,79–84,97].
In all cases, Survanta adsorption is enhanced without signiﬁcant
alteration of the Survanta interfacial properties. Albumin and
Survanta appear immiscible in the ﬂuorescence images; we observe
a well-deﬁned front of Survanta that displaces the albumin from the
interface (See Movie in Supplemental Material). However, Zuo et al.
[166] observed changes in bovine lung extract surfactant (BLES) ﬁlm
morphology and isotherms at low surface pressures which they
ascribed to albumin and BLES ﬁlm miscibility. The likely explanation
for these differences is the much larger fraction of unsaturated lipids
in BLES compared to Survanta [87], and the resulting larger fraction of
liquid expanded (LE) phase in BLESmonolayers compared to Survanta
monolayers [137]. Polyelectrolytes interact strongly with LE ﬁlms at
low surface pressures, expanding the monolayer to larger area/
molecule at a given surface pressure [213–216] through electrostatic
interactions between the polymer charges and the head groups and
by hydrophobic interactions with the tail groups of the surfactant
[215]. The extent of the modiﬁcation of the LE phases correlates with
the unsaturation of the fatty acid chains in the lipids; saturated lipids
that form LE phases only at lower surface pressures are less affected
than are unsaturated lipids that have larger area/molecule and do not
form LC phases until much higher surface pressures, if at all [216]. In
addition to increasing the area/molecule in the LE phase, many
polyelectrolytes, including chitosan, raise the collapse pressure of
unsaturated fatty acid molecules from about 30 to 45 mN/m even
though the limiting area/molecule at collapse increases from about 20
to 40 Å2/molecule [214,216]. The chitosan is likely matching the
minimum separation between charges along its backbone with the
charge separation in the fatty acid ﬁlms and the charge-coupling ofthe headgroups to the chitosan stabilizes the monolayer against
collapse, in a similar way as divalent ions increase the collapse
pressure and stability of fatty acid ﬁlms [19,214,217,218]. Hence, the
chitosan (and other polyelectrolytes [214]) appear to help stabilize
the LE phase in themonolayer. However, it is generally agreed that the
unsaturated LE phase lipids must be “squeezed-out” in favor of the LC
phase, saturated lipids that can reach the necessary near-zero surface
tensions on compression. If the unsaturated lipids in BLES ﬁlms are
not removed at low surface pressures, a higher fraction of LE phase
may be retained in the monolayer ﬁlm of BLES, which would then
result in a less stable interfacial ﬁlm and the ﬁlms may collapse at the
LE collapse pressure, which while increased by interactions with
chitosan, is still not as high as the LC phase. As Survanta has very little
LE phase at any surface pressure, chitosan would be expected to
have a much smaller effect on Survanta, as we observe. The same
explanation is likely true for the miscibility of albumin in the
surfactant ﬁlm. Zuo et al. [166] only observe albumin to be soluble
in the LE phase; the small fraction of LE phase in Survanta at high
surface pressures would cause complete exclusion of the albumin
from the Survanta ﬁlm and an immiscible displacement as is observed.
However, enhancing adsorption is not a cure-all; if the surfactant is
chemically or physically degraded by other processes associated with
ARDS, increasing the concentration of the substandard surfactant at
the interface will not eliminate inactivation [60,61]. As none of these
methods of enhancing adsorption also enhance the surfactant
properties at the interface, a poor surfactant will remain a poor
surfactant regardless of the electrolyte, polymer or polyelectrolyte
concentration. As has been shown numerous times in the literature,
not every surfactant mixture is capable of providing a ﬁlm capable of
lowering the surface tension below 10 mN/m on compression. Hence,
surfactant adsorption remains a necessary, but not sufﬁcient condi-
tion for eliminating surfactant inactivation in ARDS.
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